Method for generating human cochlear hair cells
By culturing PAX2+ ear progenitor cells in culture medium containing sound hedgehog factor activator and Wnt inhibitor and using the SHH pathway to regulate, cochlear hair cells were successfully generated, solving the difficulty in generating cochlear from human pluripotent stem cells in the prior art. The problem of hair cells has achieved the generation and functional simulation of cochlea hair cells.
Patent Information
- Application Number
- CN202280091441.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-12-09
- Filing Date
- 2022-12-09
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to generate cochlear hair cells from human pluripotent stem cells, resulting in the inability to accurately simulate human cochlear development and treat deaf-related diseases.
By culturing PAX2+ ear progenitor cells in culture medium containing sound hedgehog factor activator and Wnt inhibitor, combined with the regulation of the SHH pathway, the cell differentiation into cells expressing cochlear hair cell markers is achieved, and the generation of cochlear hair cell cells is achieved.
Cells expressing cochlear hair cell markers were successfully generated, with the structural and functional properties of cochlear hair cells, and were used to more accurately study hearing impairment and treat deaf-related diseases.
Smart Images

Figure CN118946660A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Patent Application No. 63 / 287,761, filed on December 9, 2021, the entire contents of which are incorporated herein by reference.
[0003] A note about federally funded research
[0004] This invention was made with government support under Grant W81XWH-18-1-0062 from the Defense Advanced Research Projects Agency and Grants DC015788 and DC013294 from the National Institutes of Health. The government has certain rights in this invention.
[0005] Sequence Listing
[0006] A sequence listing is attached to this application and is submitted as an xml file named "144578_00353.xml", with a size of 27,822 bytes and created on December 9, 2022. The sequence listing is submitted electronically through Patent Center, and its entire contents are incorporated herein by reference. Technical Field
[0007] The disclosed technology generally relates to methods of directing the differentiation of human pluripotent stem cells into cochlear hair cells. Background Art
[0008] The human inner ear contains the cochlea and vestibular organs, each of which contains two types of structurally distinct mechanosensitive hair cells. During embryogenesis, the cochlear organ is derived from the most ventral region of the otic capsule, while the vestibular organ is derived from an adjacent more dorsal region. The balance of morphogen gradients during embryogenesis is thought to determine the properties of the inner ear terminal organs. Previous methods of generating inner ear sensory epithelia from mouse or human pluripotent stem cell aggregates did not generate cochlear cell types because the derived hair cells only had the structural and functional properties of native vestibular hair cells. Summary of the invention
[0009] In one aspect of the present disclosure, a method for generating human cochlear hair cells is provided. In some embodiments, the method comprises: (a) culturing PAX2b derived from human pluripotent stem cells in a medium containing an activator of sonic hedgehog; +(b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days; (c) further culturing the cells of step (b) for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3, or GNG8. In some embodiments, the sonic hedgehog activator in steps (a) and (b) is purmorphamine. In some embodiments, the concentration of purmorphamine is about 1 nM to about 1 mM. In some embodiments, the Wnt inhibitor is IWP-2. In some embodiments, the concentration of IWP-2 is about 1 nM to about 1 mM. In some embodiments, the otic progenitor cells are cultured with thyroxine for about 50 days, starting from about 39 days after step (a). In some embodiments, the concentration of thyroxine in the culture medium is about 250 ng / ml. In some embodiments, the sufficient time is about 89 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, the sufficient time is about 139 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, at about 98 days after step (a), the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells express PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express two or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express three or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8.In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (a) culturing the pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) in a culture medium comprising a GSK-3 inhibitor on a coated plate for about 2 days to produce PAX2b. + In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells. In some embodiments, the concentration of BMP-4 is greater than about 100 pg / ml. In some embodiments, the concentration of BMP-4 is greater than about 500 pg / ml. In some embodiments, the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml. In some embodiments, the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
[0010] In another aspect of the present disclosure, a method is provided. In some embodiments, the method comprises: (a) culturing pluripotent stem cells in a medium containing FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium containing FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days to generate PAX2b + Progenitor cells. In some embodiments, the method further comprises: (e) culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0011] In another aspect of the present disclosure, a method is further provided. In some embodiments, the method comprises: (a) culturing pluripotent stem cells in a medium containing FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium containing FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) ) further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days; (e) further culturing the cells of step (d) in a medium containing CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium containing CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0012] In another aspect of the present disclosure, a method is further provided. In some embodiments, the method comprises: (a) culturing pluripotent stem cells in a medium containing FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium containing FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 on a coated plate for about 4 days; (c) the cells of step (e) are further cultured in a medium containing CHIR99021 for about 2 days; (e) the cells of step (d) are further cultured in a medium containing CHIR99021 and purmorphamine for about 5 days; (f) the cells of step (e) are further cultured in a medium containing CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) the cells of step (f) are further cultured in a medium containing thyroxine for about 28 days; (h) the cells of step (g) are further cultured in a medium containing thyroxine for about 50 days to generate human cochlear hair cells. In some embodiments, the culture medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0013] In another aspect of the present disclosure, human cochlear hair cells are provided. In some embodiments, the human cochlear hair cells are generated by: (a) culturing PAX2b derived from human pluripotent stem cells in a medium containing a sonic hedgehog activator; +(b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days; (c) further culturing the cells of step (b) for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3 or GNG8. In some embodiments, the concentration of purmorphamine is about 1 nM to about 1 mM. In some embodiments, the Wnt inhibitor is IWP-2. In some embodiments, the concentration of IWP-2 is about 1 nM to about 1 mM. In some embodiments, the otic progenitor cells are cultured with thyroxine for about 50 days, starting from about 39 days after step (a). In some embodiments, the concentration of thyroxine in the culture medium is about 250 ng / ml. In some embodiments, the sufficient time is about 89 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, the sufficient time is about 139 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, at about 98 days after step (a), the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells express PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express two or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express three or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8.In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (a) culturing the pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) in a culture medium comprising a GSK-3 inhibitor on a coated plate for about 2 days to produce PAX2b. + In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells. In some embodiments, the concentration of BMP-4 is greater than about 100 pg / ml. In some embodiments, the concentration of BMP-4 is greater than about 500 pg / ml. In some embodiments, the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml. In some embodiments, the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
[0014] In some embodiments, the human cochlear hair cells are generated by: (a) culturing pluripotent stem cells in a medium containing FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium containing FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days to generate PAX2b + Progenitor cells. In some embodiments, the method further comprises: (e) culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least about 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0015] In some embodiments, the human cochlear hair cells are generated by: (a) culturing pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising CHIR99021, LDN193189 and FGF-2 for about 4 days ; (d) further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days; (e) further culturing the cells of step (d) in a medium containing CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium containing CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least about 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0016] In some embodiments, the human cochlear hair cells are generated by: (a) culturing PAX2b derived from human pluripotent stem cells in a medium containing an activator of sonic hedgehog; +(b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days; (c) further culturing the cells of step (b) for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3 or GNG8. In some embodiments, the concentration of purmorphamine is about 1 nM to about 1 mM. In some embodiments, the Wnt inhibitor is IWP-2. In some embodiments, the concentration of IWP-2 is about 1 nM to about 1 mM. In some embodiments, the otic progenitor cells are cultured with thyroxine for about 50 days, starting from about 39 days after step (a). In some embodiments, the concentration of thyroxine in the culture medium is about 250 ng / ml. In some embodiments, the sufficient time is about 89 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, the sufficient time is about 139 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, at about 98 days after step (a), the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells express PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express two or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express three or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8.In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (a) culturing the pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) in a culture medium comprising a GSK-3 inhibitor on a coated plate for about 2 days to produce PAX2b. + In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells. In some embodiments, the concentration of BMP-4 is greater than about 100 pg / ml. In some embodiments, the concentration of BMP-4 is greater than about 500 pg / ml. In some embodiments, the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml. In some embodiments, the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
[0017] In another aspect of the present disclosure, an organoid is provided. In some embodiments, the organoid comprises cochlear hair cells, (a) PAX2b derived from human pluripotent stem cells is cultured in a medium comprising an activator of sonic hedgehog +(b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days; (c) further culturing the cells of step (b) for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3, or GNG8. In some embodiments, the concentration of purmorphamine is about 1 nM to about 1 mM. In some embodiments, the Wnt inhibitor is IWP-2. In some embodiments, the concentration of IWP-2 is about 1 nM to about 1 mM. In some embodiments, the otic progenitor cells are cultured with thyroxine for about 50 days, starting from about 39 days after step (a). In some embodiments, the concentration of thyroxine in the culture medium is about 250 ng / ml. In some embodiments, the sufficient time is about 89 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, the sufficient time is about 139 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, at about 98 days after step (a), the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells express PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express two or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express three or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8.In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (a) culturing the pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) in a culture medium comprising a GSK-3 inhibitor on a coated plate for about 2 days to produce PAX2b. + In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells. In some embodiments, the concentration of BMP-4 is greater than about 100 pg / ml. In some embodiments, the concentration of BMP-4 is greater than about 500 pg / ml. In some embodiments, the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml. In some embodiments, the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
[0018] In some embodiments, the organoid comprises cochlear hair cells generated by: (a) culturing pluripotent stem cells in a medium comprising FGF-2, BMP-4, and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium comprising FGF-2, SB431542, and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium comprising CHIR99021, LDN193189, and FGF-2 for about 4 days; (d) further culturing the cells of step (c) in a medium comprising CHIR99021 on a coated plate for about 2 days to generate PAX2b + Progenitor cells. In some embodiments, the method further comprises: (e) culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least about 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0019] In some embodiments, the organoid comprises cochlear hair cells generated by: (a) culturing pluripotent stem cells in a medium comprising FGF-2, BMP-4, and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium comprising FGF-2, SB431542, and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium comprising CHIR99021, LDN193189, and FGF-2 for about 1 day. 4 days; (d) further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days; (e) further culturing the cells of step (d) in a medium containing CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium containing CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a medium for about at least 78 days to generate human cochlear hair cells. In some embodiments, the medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
[0020] In some embodiments, the organoid comprises cochlear hair cells generated by: (a) culturing PAX2b derived from human pluripotent stem cells in a medium comprising an activator of sonic hedgehog; +(b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days; (c) further culturing the cells of step (b) for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3, or GNG8. In some embodiments, the concentration of purmorphamine is about 1 nM to about 1 mM. In some embodiments, the Wnt inhibitor is IWP-2. In some embodiments, the concentration of IWP-2 is about 1 nM to about 1 mM. In some embodiments, the otic progenitor cells are cultured with thyroxine for about 50 days, starting from about 39 days after step (a). In some embodiments, the concentration of thyroxine in the culture medium is about 250 ng / ml. In some embodiments, the sufficient time is about 89 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, the sufficient time is about 139 days after step (a), and wherein the culture medium does not contain additional agonists and inhibitors about 11 days after step (a). In some embodiments, at about 98 days after step (a), the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells express PRESTIN, NR2F1, GATA3 and INSM1. In some embodiments, about 98 days after step (a) begins, the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express two or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8. In some embodiments, the method results in about 98 days after step (a) begins, and the cells express three or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8.In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (a) culturing the pluripotent stem cells in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) in a culture medium comprising a GSK-3 inhibitor on a coated plate for about 2 days to produce PAX2b. + In some embodiments, the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells. In some embodiments, the concentration of BMP-4 is greater than about 100 pg / ml. In some embodiments, the concentration of BMP-4 is greater than about 500 pg / ml. In some embodiments, the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml. In some embodiments, the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
[0021] In another aspect of the present disclosure, kits, platforms and systems are provided. In some embodiments, the kit, system or platform comprises: (a) a sonic hedgehog activator; and (b) a Wnt inhibitor. In some embodiments, the kit, system or platform further comprises: (c) FGF-2; (d) a TGF-β inhibitor; (e) a BMP-4 inhibitor; and (f) a GSK-3 inhibitor. In some embodiments, the kit, system or platform further comprises: (g) thyroxine. In some embodiments, the kit, system or platform further comprises: (h) an induced pluripotent stem cell or an embryonic stem cell.
[0022] BRIEF DESCRIPTION OF THE DRAWINGS
[0023] Figure 1a ,1b-1l.PAX2-2A-nGFP / POU4F3-2A-ntTomato(PAX2 nG / POU4F3 nT) Multiple reporter hESCs faithfully recapitulate otic progenitor and hair cell differentiation in inner ear organoids. a, Schematic representation of the PAX2-2A-nGFP and POU4F3-2A-ntdTomato CRISPR designs. Two pairs of 1 kb homology arms flanked by stop codons for the otic dominant PAX2b splice variant and the POU4F3 unique splice variant were generated by PCR. The PAX2 construct contains a floxed PGK-puromycin cassette, which is used to positively select correctly targeted clones and is subsequently removed by CRE recombination following transfection with a CRE recombinase expression vector. The POU4F3 construct contains a PGK-puromycin cassette flanked by FLPo, which is subsequently removed following transfection with a FLPo recombinase expression vector. A viral p2A sequence was included to generate separate gene products from polycistronic mRNA transcripts. A nuclear localization sequence was included to allow for proper localization visualization. A single guide RNA was used to maximize insertion efficiency and minimize off-target activity. b, PAX2 during inner ear organoid development nG and POU4F3 nT Schematic diagram of reporter expression. cf, Live image of whole aggregates containing multiple developing inner ear organoids showing expression of PAX2 nG Temporal-spatial progression of reporter expression and early morphogenesis of PAX2+ epithelium. gh, Representative images of hESC-derived aggregates showing PAX2 nG + epithelial cells assembled into vesicles that co-expressed the ear-specific marker FBXO2 but lacked POU4F3 nT i-i', Live images of late (D96) aggregates showing strong POU4F3 localization to epithelial vesicles nT + spots. jl, POU4F3 in inner ear organoids nT + cells also express the hair cell markers MYO7A, ATOH1, and SOX2 and are located on the luminal surface of the SOX2+ supporting epithelium. Scale bars, 200 μm (cg, h, i, i'), 50 μm (g', h'), 10 μm (jl).
[0024] Figure 2a-2c . Optimization of the inner ear organoid derivation protocol. a, Schematic comparison of the inventors' original protocol and the optimized protocol. b, Real-time image of whole-cell aggregates containing inner ear organoids derived from the inventors' PAX2 nG / POU4F3 nTMultiple reporter hESC lines cultured according to the original protocol versus the optimized protocol. c, Quantitative comparison of culture results of the optimized protocol versus the original protocol. n = 20 (green histogram), 13 (red histogram) biological samples per group, from separate experiments. Welch's two-sided t-test ***P = 0.000132, ****P = 0.000013 (# of cysts) P < 0.000001 (diameter) Scale bar, 200 μm.
[0025] Figure 3a , 3b, 3c, 3d, 3e, 3f. PUR+IWP2 treatment promotes ventralization of middle ear progenitor cells in human inner ear organoids. a, Schematic diagram of known ventralization and dorsalization signals during mouse inner ear development and the application of this principle in the human inner ear organoid system. bd, PAX2 sorted by FACS in human inner ear organoids nG + D20 scRNA-seq analysis of otic progenitors. UMAP projections of otic progenitors from PUR+IWP2, PUR, and CTRL samples (b). Feature plots indicate that dorsal otic markers are predominantly expressed in PUR and CTRL otic progenitors, whereas ventral otic markers and SHH signaling components are primarily restricted to PUR+IWP2 cells. Consistent with this, volcano plots (c) show differential expression of dorsal and ventral otic marker genes between PUR+IWP2 and CTRL otic progenitors. Gene set enrichment analysis of upregulated genes (above and below 0 in the bubble plot, respectively) in PUR+IWP2 and CTRL otic progenitors (d) shows that genes associated with posttranscriptional regulation of gene expression, chromatin modifications, and Hedge Hog signaling are enriched in ventral otic progenitors of inner ear organoids. (e) Representative images of D25 samples show that NR2F1 and SUlF1 are significantly more highly expressed in PUR+IWP2 organoids compared to CTRL organoids. (f) Quantification of vesicles co-expressing PAX2 and NR2F1 (or SULF1) in PUR+IWP2 and CTRL organoids; n = 8 biological samples per group, from separate experiments; Welch's two-sided t-test *P = 0.0013 (NR2F1), **P = 0.0089 (SULF1); values are mean ± SEM. Scale bar, 200 μm.
[0026] Figure 4a , 4b , 4c, 4d, 4e, 4f, 4g. POU4F3 in ventralized inner ear organoids nT + cells express cochlear hair cell markers. ad, POU4F3 isolated from D109 PUR+IWP2 and CTRL inner ear organoids nT+ cells (a). Feature maps showing differential expression of known cochlear and vestibular marker genes in annotated hair cell clusters (b). Volcano plots (c) confirm differential expression of cochlear and vestibular hair cell marker genes between PUR+IWP2 and CTRL hair cells. In addition, previously unidentified genes, such as NR2F1, TMPRSS3, CD164L2, ZBBX, and SKOR1, are differentially expressed between PUR+IWP2 and CTRL hair cells. Heatmap showing gene expression for each cluster (d). e, Representative immunohistochemistry validates differential expression of NR2F1 and GATA3 between PUR+IWP2 and CTRL inner ear organoids. f, Comparison of the percentage of NR2F1- or GATA3-positive hair cells and supporting cells in PUR+IWP2 versus CTRL inner ear organoids; n = 9 biological samples from separate experiments; Welch's two-sided t-test ****P<0.000001; Values are mean ± SEM. g, NR2F1 and GATA3 are expressed in both outer and inner hair cells in human cochlea at GW18. Scale bar, 20 μm (e, g).
[0027] Figure 5a-5o , 5p, 5q. Hair cells derived from ventralized organoids exhibit structural properties of cochlear hair cells. a-h', Scanning electron micrographs of PUR+IWP2 hair bundles (ab, fg) reveal relatively short stereocilia organized into concave rows with increasing height and diameter, which is characteristic of the cochlear hair cell phenotype. In contrast, scanning electron micrographs of CTRL hair bundles (ce, h-h') show slender stereocilia organized into convex rows with diameter characteristics identical to those of native vestibular hair cells. i-k', Confocal micrographs of PUR+IWP2-treated hair cells (i-i') show short F-actin + The hair bundles and rectangular soma with basally located nuclei, while confocal microscopy images of CTRL hair cells (j-k') show elongated F-actin + Hair bundles and somata that are usually spherical or flask-shaped. Even at D200, CTRL hair cells retain vestibular morphology (j). pq, Quantification of stereocilia height and individual stereocilia diameter in PUR+IWP2 (lm) and CTRL hair cells (j-k'); n = 50 biological samples from separate experiments; Welch's two-sided t-test ****P < 0.00001; Values are mean ± SEM Scale bars, 10 μm (c, i, j, k), 1 μm (a, b, dh, k').
[0028] Figure 6a , 6b, 6c, 6d, 6e, 6f, 6g, 6h. A subset of hair cells derived from ventralized organoids express PRESTIN and exhibit voltage-gated currents characteristic of cochlear outer hair cells. ab, PRESTIN+ hair cells increase over time in PUR+IWP2 inner ear organoids. Representative immunohistochemistry for PRESTIN in PUR+IWP2 samples at D102, -150, and -200, and comparison of the percentage of hair cells expressing PRESTIN at different ages demonstrate that the number of hair cells expressing membrane PRESTIN increases over time in culture. In contrast, PRESTIN is undetectable in CTRL hair cells at D110 or -200. c, Live images of tdTomato-positive samples cut with a diamond knife. dh, Voltage-gated currents in hESC-derived hair cells. Representative whole-cell current responses (top traces) to a voltage step protocol (bottom traces) in type A (d) and type B (e) cells. Average steady-state current amplitude at the end of the voltage step in type A (f) and type B (h) cells. Peak amplitude of negative inward current (g). All data are shown as mean ± standard error. Cell age: D138-D164. Scale bar, 10 μm (a), 200 μm (c).
[0029] Figure 7a-7C. Thyroxine treatment increases the number of PRESTIN+ HCs in cochlear organoids. (a) The number of Prestin-positive HCs increases when organoids are treated with 250 ng / mL thyroxine. (b) Quantification of Prestin+ HCs over time in thyroxine-treated and untreated organoids. (c) Thyroxine-treated HCs downregulate the immature HC marker SOX2, while SOX2 expression is maintained in SCs, recapitulating the process of cochlear maturation.
[0030] Figure 8a , 8b, 8c 8d, 8e, 8f, 8g.PAX2-2A-nGFP (PAX2 nG ) Generation and validation of reporter hESC lines. ab, Schematic diagram of PAX2 isoforms (a), RT-PCR data showing that PAX2b is the most abundantly expressed isoform in stem cell-derived inner ear organoids (b). cd, Using ( Figure 1a ) showed biallelic insertion of the 2A-nGFP cassette at the PAX2 locus (c), which was confirmed by Sanger sequencing (d). e, undifferentiated PAX2 nG Immunofluorescence of hESCs reveals expression of multiple pluripotency markers and constitutive PAX2 nG Lack of reporter expression. f, PAX2 in sections nGRepresentative immunohistochemistry of hESC-derived inner ear organoids showing expression of PAX2 at D20 nG Localized to epithelial vesicles, it co-expresses the ear marker PAX8, and at D25, SOX10 and FBXO2. PAX2 nG The expression of PAX2 was continuous and could be detected by real-time imaging at D70. nG Sox2 / Myo7a+ hair cells were detected on the luminal surface of + vesicles. g, Sequencing of the top 10 predicted off-target CRISPR sites showed no insertions or deletions in surrounding loci. Scale bars, 50 μm (e) and 200 μm (f).
[0031] Figure 9a , 9b, 9c-9f”, 9g, 9h.PAX2-2A-nGFP / POU4F3-2A-ntdTomato (PAX2 nG / POU4F3 nT ) Generation and validation of reporter hESC lines. ab, PCR amplification of the POU4F3 locus shows biallelic insertion of the 2A-ntdTomato reporter cassette (a). Sanger sequencing reveals the correct insertion and orientation of the reporter cassette just downstream of the POU4F3 stop codon (b). cd, POU4F3 at D60 and -100 nT Expression of the reporter is restricted to cells on the luminal surface of the vesicle. e, Dissociated POU4F3 isolated from D80 inner ear organoids nT Fixed cell suspension of + cells showing tdTomato+ nuclei, F-actin+ membranes and stereocilia. ff", by POU4F3 nT Immunohistochemistry of hESC-derived D110 inner ear organoids shows that tdTomato+ dots mark the nuclei of PCP4+ hair cells and colocalize well with antibody-labeled POU4F3. g, Sequencing of the top 10 predicted off-target CRISPR sites shows no insertions or deletions in the surrounding loci. h, PAX2 nG / POU4F3 nT hESC lines showed normal karyotyping results. Scale bars, 200 μm (c, d), 10 μm (e), 100 μm (f).
[0032] Fig.10a, 1b, 10c. Optimization of BMP4 concentrations to induce the formation of non-neural ectoderm and downstream cochlear organoids. a. Representative live images of cell aggregates over time with different concentrations of recombinant BMP4 applied on day 0. Otherwise, cultures were maintained as described for the inner ear and cochlear differentiation protocols. b, Quantification of GFP+ area fraction in live images on day 20; n = 4 aggregates per condition; one-way ANOVA, Dunnet’s multiple comparison test, *P < 0.01. c, Population proportion of cell aggregates expressing TdTomato at day 55. Scale bar, 200 μm (a).
[0033] Figures 11a-11g . PAX2 in D20 CTRL, PUR and PUR+IWP2 inner ear organoids nG Cells were subjected to scRNA-seq analysis. a, FACS gating strategy used to isolate PAX2 from whole aggregates nG + cells. b, Cell clusters were generated by Seurat and visualized using UMAP. c, Dot plots show the relative expression of marker genes in annotated clusters. d, Feature plots show classical markers for otic progenitors, neuroblasts, and cycling cells. e, Colored cells show the distribution of conditions within each cluster. Stacked histograms show the composition of each cluster by condition. f, Representative immunohistochemistry of D25 organoid sections shows differential expression of OTX2 and DLX3 between conditions. g, Quantitative comparison of OTX2 and DLX3 expression between PUR+IWP2 and CTRL conditions by immunohistochemistry; n = 5 biological samples per group from separate experiments; Welch’s two-sided t-test **P < .001; ***P < 0.0001; Values are mean ± SEM. Scale bar, 200 μm.
[0034] Fig.12a , 12b, 12c-12h, 12i, 12j. Protein kinase A inhibitors fail to promote hair cell differentiation. a, Representative immunohistochemistry of regionally expressed ear markers OTX2, GATA3, and DLX3 in D25 inner ear organoids treated with or without 10 μM H89 alone or in combination with PUR or PUR+IWP2. b, Schematic representation of the proposed role of H89 in the SHH pathway. c, Live images of D102 cell aggregates treated with H89 and PUR show single POU4F3 nT + inner ear organoids. d, Representative images of D102PUR+H89 treated aggregates showing low levels of POU4F3 nT + spots. e, Immunohistochemistry of D102 inner ear organoids treated with H89+PUR showed that there were POU4F3 on the luminal surface of SOX2+ epithelial cells. nT+ nuclei of MYO7A+ hair cells and. f, Confocal images of hair cells in H89+PUR treated organoids show detectable expression of the cochlear outer hair cell marker LMOD3. gh, Immunohistochemistry of D102 H89+PUR treated inner ear organoids stained with phalloidin shows hair bundles with vestibular-like length and morphology. i, Quantitative comparison of OTX2, GATA3, and DLX3 expression between different treatment groups; n = 5 biological samples per group from separate experiments; *P < 0.01; values are mean ± SEM. j, Quantitative comparison of the percentage of tdTomato expressing aggregates (left y axis) and the total tdTomato positive area per aggregate (right y axis) between different treatment groups; n = 12 biological samples per group from separate experiments; Welch two-sided t test *P < 0.01; ns, not significant; values are mean ± SEM. Scale bars, 200 μm (ad), 20 μm (eg), 5 μm (h).
[0035] Fig.13a , 13b, 13c, 13d, 13g. FACS sorted POU4F3 in D80 CTRL and PUR+IWP2 inner ear organoids nT + cells scRNA-seq analysis. a, UMAP projection shows the annotated POU4F3 nt + cell clusters. b, Feature plot showing the distribution of inner ear and neural marker genes. c, Dot plot showing the relative expression of marker genes in annotated clusters. d, Volcano plot depicts differentially expressed genes between PUR+IWP2 and CTRL hair cells, shown in magenta and blue, respectively. g, Feature plot and accompanying violin plots showing the distribution of cochlear and vestibular gene expression on the cluster plot and between PUR+IWP2 and CTRL hair cells, shown in magenta and blue, respectively.
[0036] Fig.14a , 14b, 14c, 14d, 14e, 14f, 14g, 14h. FACS sorted POU4F3 in D109 CTRL and PUR+IWP2 inner ear organoids nT scRNA-seq analysis of POU4F3+ cells. a, FACS gating strategy used to isolate POU4F3 from dissociated 109-day internal otic organoids under PUR+IWP2 and CTRL conditions. nT + cells. b, Feature graph showing the distribution of marker genes on the cluster graph. c, Dual feature graph showing the expression patterns of GATA3 and MEIS2. d, POU4F3 under PUR+IWP2 conditions nTPseudo-temporal analysis of LGR5+ cells revealed branching trajectories for LGR5+ cells to adopt hair cell-like or supporting cell-like fates. e, Violin plots depicting the distribution of cochlear and vestibular marker genes in PUR+IWP2 and CTRL conditions, shown in magenta and blue, respectively. f, Gene set enrichment analysis of genes upregulated in PUR+IWP2 and CTRL conditions (above and below 0 in the bubble plots, respectively) showed that gene sets associated with voltage-gated cation channel activity were upregulated in hair cells of PUR+IWP2 inner ear organoids compared with CTRL organoids. g, Representative immunohistochemistry showed differential expression of INSM1 and NDGR1 between PUR+IWP2 and CTRL inner ear organoids. h, Quantitative comparison of INSM1 and NDGR1 expression levels in PUR+IWP2 and CTRL inner ear organoids; n = 5 biological samples per group from separate experiments; Welch two-sided t-test *P = 0.001468, ***P < 0.000012; Values are mean ± SEM. Scale bar, 20 μm.
[0037] Figures 15a-15g , 15h-15m'. Hair cells in PUR+IWP2 and CTRL inner ear organoids exhibit distinct hair bundle morphology. ac"', Scanning electron micrographs of hair bundles of PUR+IWP2-treated cells show the development of hair bundle organization, including the assembly of tip links. d-d', Scanning electron micrographs show the enlarged diameter of stereocilia on the apical surface of PUR+IWP2 hair cells. ef, Confocal micrographs show short F-actin+ stereocilia on the apical surface of PUR+IWP2-treated hair cells at D110 and -200. g, TUJ1+ neurites contact PUR+IWP2 hair cells at D200. hk, Scanning electron micrographs of CTRL hair bundles show the long, pointed morphology with Stereocilia of uniform diameter. l-l', Confocal microscopy images show that CTRL hair cells have long and pointed F-actin+ stereocilia on their surface. m-m', TUJ1+ neurites contact CTRL hair cells at day 200. Scale bars, 1 μm (a, b, c, d), 500 nm (a', c', d', j, k), 100 nm (c", c''), 10 μm (e', h, i, l', m'), 20 μm (e, f, g, l, m).
[0038] Figure 16a-16e”. The timeline of human inner ear organoid development closely reflects that of human fetal inner ear development. Schematic diagram depicting the timing of developmental events observed in the development of the native human cochlea and in human cochlear organoids in this study. a-c”, Low-magnification modiolar sections of human GW13 cochlea (a) and immunofluorescence images showing the presence of inner and outer hair cells (b-b’) and the lack of PRESTIN expression in cochlear hair cells at this stage (cc”). de”, Low-magnification modiolar sections of human GW18 cochlea (d) and immunofluorescence images showing membrane PRESTIN expression in outer hair cells (ee”). Scale bars, 1000 μm (a, d), 50 μm (b, c, e), 20 μm (b’, c’, e’).
[0039] Fig.17 .Exemplary timeline of the inner ear organoid protocol. Fig.17 The exemplary protocol depicted in the Figure 1 begins with aggregated stem cells at D0 and produces Pax2b at D11-D13. + Auricular progenitor cells and PRESTIN production after approximately 100 days of culture + Cochlear hair cells. DETAILED DESCRIPTION
[0040] The inventors have developed a next-generation organoid system to generate cochlear hair cells from human pluripotent stem cells. This in vitro model system can be used to more accurately study hearing impairment and therapies for diseases and conditions associated with cochlear hair cell dysfunction or loss, including deafness. The inventors have developed a method to direct the differentiation of human pluripotent stem cells into cochlear hair cells that can transmit hearing. The inventors have previously developed methods to generate inner ear sensory epithelium using aggregates of mouse or human pluripotent stem cells, but the main limitation of this system is the lack of cochlear cell types, as the derived hair cells only have the structural and functional properties of native vestibular hair cells. Here, a next-generation organoid system for generating cochlear hair cells from human pluripotent stem cells is provided, which can be used as an in vitro model system to more accurately study hearing impairment and treatment modalities.
[0041] Method for deriving cochlear hair cells from pluripotent stem cells in vitro
[0042] In one aspect of the present disclosure, a method for generating human cochlear hair cells is provided. In some embodiments, the method for generating human cochlear hair cells comprises (a) culturing PAX2 derived from human pluripotent stem cells in a medium containing an activator of sonic hedgehog +(b) subsequently culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the following cochlear hair cell markers: GATA3, NR2F1, INSM1 or PRESTIN. Preferably, the human cochlear hair cells can transmit hearing, see Figure 6d-6f .
[0043] PAX2b + The otic progenitor cells may be derived from pluripotent stem cells. Suitably, PAX2b + The cells were derived from human pluripotent stem cells at day 10-13 (day 0 is the start of differentiation medium, see e.g. Figures 2a and 3a). In this case, PAX2b + The ear progenitor cells are cultured with an agonist of sonic hedgehog from about day 13 to about day 22. The cells are then cultured with a Wnt inhibitor from about day 18 to about day 22. Unexpectedly, by adding a Wnt inhibitor to the SHH agonist, the method is able to differentiate the cells into cochlear hair cells expressing GATA3, NR2F1 or INSM1. The expression of a given marker (e.g., GATA3, NR2F1 or INSM1) can be measured by any known technique (e.g., RNA sequencing, quantitative PCR (qPCR), enzyme-linked immunosorbent assay (ELISA), etc.). PAX2b + The ear progenitor cells can be differentiated by: (a) culturing pluripotent stem cells in a medium containing FGF-2, BMP-4 and SB431542 on a coated plate for about 3 days; (b) further culturing the cells of step (a) in a medium containing FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium containing CHIR99021, LDN193189 and FGF-2 for about 4 days; and further culturing the cells of step (c) in a medium containing CHIR99021 on a coated plate for about 2 days to generate PAX2b + Ear progenitor cells.
[0044] As used herein, "cochlear hair cells" refer to cells in the cochlea that transmit hearing. There are two types of cochlear hair cells in the cochlea of a normal person, namely inner hair cells and outer hair cells. Outer hair cells have electrokinetic properties, which synchronize the length of the cells with the incoming sound signals, thereby providing mechanical amplification for the sound signals. This effect is called the "cochlear amplifier", which is believed to improve the frequency selectivity of the mammalian ear. Outer hair cells are characterized in that they express the motor protein PRESTIN encoded by the gene SLC26A5. Inner hair cells detect acoustic vibrations in the cochlear fluid and convert them into electrical signals, which are transmitted to the brain through the auditory nerve. The cochlear hair cells derived herein can be detected using one or more markers selected from GATA3, INSM1, NR2F1, HES6, TMPRSS3, GNG8 or PRESTIN. In some embodiments, the cochlear hair cells express two or more markers selected from GATA3, INSM1, NR2F1, HES6, TMPRSS3, GNG8 or PRESTIN, and in some alternative embodiments, the cells express three or more markers or four or more markers selected from GATA3, INSM1, NR2F1, HES6, TMPRSS3, GNG8 or PRESTI. In one embodiment, the cochlear hair cells express four markers GATA3, NR2F1, INSM1 and PRESTIN, and in some embodiments, further express one or more markers selected from HES6, TMPRSS3 and GNG8.
[0045] In contrast, "vestibular hair cells" are hair cells that transmit the sense of balance and gravity. The vestibular apparatus includes the semicircular canals, utricle, and saccule. During development, the cochlea arises from the most ventral region of the otic capsule, while the vestibular structures arise from the more dorsal ear region (and therefore express dorsal ear markers).
[0046] Thus, the inner ear cells of the cochlea are said to be "ventralized" compared to the inner ear cells of the vestibular organ. Thus, in certain embodiments, the invention disclosed herein demonstrates a new method of generating ventral hair cells compared to previous methods of generating dorsal / vestibular hair cells.
[0047] This approach used aggregates of human pluripotent stem cells and found that modulation of sonic hedgehog and WNT signaling promoted the expression of ventral otic markers by stem cell-derived otic progenitors. Strikingly, some of these ventral otic progenitors gave rise to hair cells with short hair bundles containing stereocilia arranged in a geometry resembling cochlear hair cells. Furthermore, these ventral hair cells expressed multiple markers that define either outer or inner hair cells of the cochlea. These results suggest that early morphogenetic signals are sufficient not only to establish cochlear gene expression but also to determine structural properties associated with the cochlear sensory epithelium.
[0048] Next, the inventors discovered that timed activation of the sonic hedgehog (SHH) pathway, accompanied by inhibition of protein kinase A (PKA), bone morphogenetic protein (BMP) and / or wingless (WNT or Wnt) signaling, can promote the upregulation of ventral ear genes, thereby generating cochlear hair cells in long-term culture. Briefly, ear progenitor cells are cultured in a culture medium containing a sonic hedgehog signaling activator (SHH activator) for at least 3 to 5 days. Then, the cells are cultured in a culture medium containing a SHH activator and a Wnt inhibitor for a sufficient time to differentiate the cells into human cochlear hair cells expressing one or more of the cochlear hair cell markers GATA3, INSM1, NR2F1 or PRESTIN. In some embodiments, cochlear hair cells express PRESTIN. In some embodiments, ear progenitor cells are cultured with a SHH activator from about day 13 to about day 22, for example, for about 10, 9, 8, 7, 6, 5, 4, 3 or 2 days. In some embodiments, the otic progenitor cells are cultured with a Wnt inhibitor from about day 18 to about day 22, e.g., for about 6, 5, 4, 3, 2, or 1 day, and the aggregated stem cells are cultured in a medium comprising a TGF-β inhibitor, FGF2, and optionally BMP-4 starting on day 0 (see FIG. 2a ). In the present disclosure, it is understood that culture D0 begins at the initiation stage of generating otic progenitor cells from pluripotent stem cells (see FIG. 2A ).
[0049] The inventors have found that when implementing the disclosed methods, long-term culture (e.g., more than 50 days) can produce cells expressing mature cochlear hair cell markers (e.g., PRESTIN). Therefore, in some embodiments, after culturing the cells in a medium containing an SHH activator and a Wnt inhibitor, the cells are further cultured in an organoid maturation medium (OMM). OMM contains a 50:50 mixture of advanced DMEM:F12 (Thermo Fisher, 12634028) and a neurobasal medium (Thermo Fisher, 21103049) supplemented with 0.5×N2 supplement (Thermo Fisher, 17502048), 0.5×B27 minus vitamin A (Thermo Fisher, 12587010), 1×GlutaMAX (Thermo Fisher, 35050061), 0.1 mM β-mercaptoethanol (Thermo Fisher, 21985023) and Normocin. In some embodiments, cells are further cultured in OMM, for example, for about 50, 60, 70, 80, 90, 100, 150 days or more. In some embodiments, the cell culture time exceeds about 100 days, or exceeds about 150 days. In some embodiments, long-term culture causes cells to express one or more markers selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3 and GNG8, measured by the expression of mRNA or protein, etc. The detection of markers can be carried out using any test known in the art for detecting the expression of target molecules, such as immunofluorescence (IF), immunohistochemistry (IHC), fluorescent or luminescent reporters, quantitative polymerase chain reaction (qPCR), RNA sequencing (RNA-seq), single cell RNA sequencing (scRNA-seq), etc.
[0050] Exemplary SHH activators include, but are not limited to, the compound SAG (3-chloro-N-[trans-4-(methylamino)cyclohexyl]-N-[[3-(4-pyridinyl)phenyl]methyl]-benzo[b]thiophene-2-carboxamide dihydrochloride) and purmorphamine, an agonist of smoothened protein, (9H-purin-6-amine, 9-cyclohexyl-N-[4-(4-morpholinyl)phenyl]-2-(1-naphthyloxy)-. In some embodiments, the SHH activator is purmorphamine. Suitable concentrations are known in the art. In some embodiments, the concentration of the SHH activator in the culture medium is about 1 nM to about 1 mM, and suitably the activator is purmorphamine.
[0051] Exemplary Wnt inhibitors include, but are not limited to, IWP-2 (N-(6-methyl-2-benzothiazolyl)-2-[(3,4,6,7-tetrahydro-4-oxo-3-phenylthieno[3,2-d]pyrimidin-2-yl)sulfanyl]-acetamide), Wnt-C49 (2-(4-(2-methylpyridin-4-yl)phenyl)-N-(4-(pyridin-3-yl)phenyl))acetamide), IWP L6 (2-[(4-oxo-3-phenyl-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(5-phenylpyridin-2-yl)acetamide), and IWP 12(2-[(3,6-dimethyl-4-oxo-6,7-dihydrothieno[3,2-d]pyrimidin-2-yl)sulfanyl]-N-(6-methyl-1,3-benzothiazol-2-yl)acetamide). In some embodiments, the Wnt inhibitor is IWP-2. A person skilled in the art can determine the appropriate concentration. For example, in some embodiments, the concentration of the Wnt inhibitor in the culture medium is about 1 nM to about 1 mM. The Wnt inhibitor can be IWP-2 and is used at a concentration of about 1 nM to about 1 mM.
[0052] Exemplary TGF-β inhibitors include SB-431542, Galunisertib (LY2157299), LY2109761, SB525334, SB505124, GW788388, LY364947, RepSox (E-616452), TGFβRI-IN-3, R-268712, BIBF-0775, TP0427736 HCl, A-83-01, SD-208, and Vactosertib (TEW-7197). The TGF-β inhibitor may be, preferably, SB-431542.
[0053] As described above, cells cultured with SHH activators and Wnt inhibitors can be further cultured beyond the first 22 days, for example, cells can be further cultured for at least 50 days, or more than about 100 days, wherein the culture medium after about day 22-25 does not contain additional agonists or inhibitors after about day 22-25. In some embodiments, after washing the cells, the cells are transferred to a culture medium without additional agonists or inhibitors. In some embodiments, the cells are cultured in a culture medium without additional agonists or inhibitors for more than about 150 days.
[0054] The inventors have found that culturing cells in the presence of thyroxine (e.g., 250 ng / ml thyroxine) from about day 50 to about day 100 results in increased expression of PRESTIN in the cells. Thus, after about 22-25 days, the cells can be cultured without additional agonists or inhibitors other than thyroxine. Cells cultured for this long term express cochlear hair cell markers, such as PRESTIN. In addition, the cells express two or more markers, or three or more markers, or four or more markers, or five or more markers, or all six markers, associated with cochlear hair cells, selected from PRESTIN, GATA3, INSM1, HES6, TMPRSS3, and GNG8.
[0055] In some cases, the semisolid composition of the extracellular matrix protein is a commercially available product, e.g. Basement membrane matrix. Basement membrane matrix is suitable for use hESC SFM or Essential 8 TM In other cases, the semi-solid composition comprises two or more extracellular matrix proteins, such as laminin, entactin, vitronectin, fibronectin, collagen, Matrigel, TM or a combination thereof.
[0056] In some embodiments, the methods of the present disclosure begin with a method for generating "otic progenitor cells." Otic progenitor cells are characterized by expression of PAX2 (e.g., PAX2 + In some embodiments, before cells are induced to become otic progenitor cells, they aggregate together. To form aggregates, pluripotent stem cells from confluent culture can be removed from a surface (e.g., ) into clumps, aggregates or single cells. In some embodiments, the culture medium for aggregating the disclosed cells comprises Essential 8Flex medium (Thermo Fisher, A2858501) supplemented with 100 μg / ml Normocin (E8fn) on a suitable matrix (e.g., recombinant human vitronectin-N, collagen, matrigel, etc.). In some embodiments, the culture medium for aggregating the disclosed cells comprises Essential 8Flex medium (Thermo Fisher, A2858501) supplemented with 100 μg / ml Normocin (E8fn) on a suitable matrix (e.g., recombinant human vitronectin-N, collagen, matrigel, etc.). TM (StemCell Technologies; Vancouver, British Columbia, Canada) and TeSR TM), dissociated cells (as clumps, aggregates or single cells) are plated onto a surface. TeSR was described by Ludwig et al. TM See, for example, Ludwig T et al., "Feeder-independent culture of human embryonic stem cells," Nat. Methods 3:637-646 (2006); Ludwig T et al., "Derivation of human embryonic stem cells in defined conditions," Nat. Biotechnol. 24:185-187 (2006), which are incorporated herein by reference in their entirety. Other DMEM formulations suitable for use herein include, for example, X-Vivo (BioWhittaker, Walkersville, Md.) and (Invitrogen, Carlsbad, CA).
[0057] As used herein, the term "pluripotent cell" refers to a cell that can be differentiated into all three germ layers (i.e., ectoderm, mesoderm, and endoderm). Examples of pluripotent cells include embryonic stem cells and induced pluripotent stem cells (iPS). As used herein, "iPS cells" refer to cells that are substantially identical to their respective primary differentiated somatic cells in genes, and show characteristics similar to higher potential cells (such as ES cells), as described herein. The cell can be obtained by reprogramming non-pluripotent (e.g., pluripotent or somatic) cells. Pluripotent stem cells (PSCs) suitable for the differentiation methods disclosed herein include, but are not limited to, human embryonic stem cells (hESCs), human induced pluripotent stem cells (hiPSCs), non-human primate embryonic stem cells (nhpESCs), and non-human primate induced pluripotent stem cells (nhpiPSCs).
[0058] Subject-specific somatic cells for reprogramming into iPS cells can be obtained or isolated from a target tissue of interest by tissue biopsy or other tissue sampling methods. In some cases, the subject-specific cells are processed in vitro before use. For example, the subject-specific cells can be expanded, differentiated, genetically modified, contacted with polypeptides, nucleic acids or other factors, cryopreserved or otherwise modified.
[0059] Defined medium and substrate conditions for culturing pluripotent stem cells (such as those used in the methods described herein) are well known in the art. In some exemplary embodiments, pluripotent stem cells to be differentiated according to the methods disclosed herein are cultured in accordance with the manufacturer's protocol. -1 medium (Stem Cell Technologies, Inc., Vancouver, CA) or Essential Culture medium (Life Technologies Corporation) On the surface or, in some cases, The cells were cultured on BD Biosciences substrate (BD Biosciences, NJ).
[0060] In some embodiments, the aggregates of pluripotent stem cells are optionally cultured in the presence of a Rho kinase (ROCK) inhibitor. It is known that kinase inhibitors (such as ROCK inhibitors) can protect single cells and small cell aggregates. See, for example, U.S. Patent Application Publication No. 2008 / 0171385, the entire contents of which are incorporated herein by reference; and Watanabe K et al., "A ROCK inhibitor permits survival of dissociated human embryonic stem cells", Nat. Biotechnol. 25: 681-686 (2007), which is incorporated herein by reference. As shown below, ROCK inhibitors can significantly improve the survival of pluripotent cells on chemically defined surfaces. ROCK inhibitors suitable for use herein include, but are not limited to, (S)-(+)-2-methyl-1-[(4-methyl-5-isoquinolyl)sulfonyl]homopiperazine dihydrochloride (informal name: H-1152), 1-(5-isoquinolinesulfonyl)piperazine hydrochloride (informal name: HA-100), 1-(5-isoquinolinesulfonyl)-2-methylpiperazine (informal name: H-7), 1-(5-isoquinolinesulfonyl)-3-methylpiperazine (informal name: iso H-7), N-2-(methylamino)ethyl-5-isoquinoline-sulfonamide dihydrochloride (informal name: H-8), N-(2-aminoethyl)-5-isoquinolinesulfonamide dihydrochloride (informal name: The kinase inhibitors may be provided in sufficiently high concentrations to allow cells to survive and remain attached to the surface. Inhibitor concentrations of about 3 μM to about 10 μM may be suitable for use in the disclosed methods. At lower concentrations, or when no ROCK inhibitor is provided, undifferentiated cells typically detach while differentiated cells remain attached to the defined surface.
[0061] To induce the formation of otic progenitor cells, aggregated pluripotent stem cells are cultured in a medium containing a transforming growth factor β (TGF-β) signaling inhibitor, such as SB-431542, bone morphogenetic protein (BMP-4), and a low concentration of fibroblast growth factor 2 (FGF-2) for about 3 days. The inventors found that culturing aggregated stem cells with BMP-4 at this stage of the differentiation protocol increased POU4F3 at D55 after the start of culturing the aggregates. + The proportion of cells ( Fig.10a ). In addition, the concentration of BMP-4 affects the expression of POU4F3 + The proportion of cells ( Fig.10b , 10c), its concentration may be greater than about 100pg / ml, greater than about 200pg / ml, greater than about 300pg / ml, greater than about 400pg / ml, greater than about 500pg / ml, greater than about 600pg / ml, greater than about 700pg / ml, greater than about 800pg / ml, greater than about 900pg / ml. The concentration of BMP-4 can be about 100pg / ml to about 500pg / ml (e.g., about 200, 300, 400 or 500pg / ml), or about 500pg / ml to about 1000pg / ml (e.g., about 500, 600, 700, 800, 900 or 1000pg / ml). Then, the cells are cultured in a medium containing a bone morphogenetic protein 4 (BMP-4) signaling inhibitor, such as LDN193189, and a high concentration of FGF-2 for about 4 days, and then the cells are cultured in a medium containing a high concentration of FGF-2, a BMP-4 signaling inhibitor, and a glycogen synthase kinase 3 (GSK-3) inhibitor (such as CHIR99021) for about 4 days. See Figure 2a.
[0062] In some embodiments, the otic progenitor cells are derived from pluripotent stem cells by the following method: (i) from day 0 to day 3, culturing the pluripotent stem cells in a medium comprising FGF-2 and a TGF-β inhibitor (e.g., SB-431542) on a coated plate; (ii) from day 3 to day 7, culturing the cells of step (i) in a medium comprising FGF-2, a TGF-β inhibitor, and a BMP-4 inhibitor (e.g., LDN 193189); (iii) from day 7 to day 11, culturing the cells of step (ii) in a medium comprising a GSK-3 inhibitor (e.g., CHIR99021), a BMP-4 inhibitor; and (iv) from day 11-18, culturing the cells of step (iii) in a medium comprising a GSK-3 inhibitor on a coated plate to produce PAX + Ear progenitor cells.
[0063] Cell composition
[0064] In another aspect of the present disclosure, a cell composition is provided. In some embodiments, the composition comprises human cochlear hair cells or comprises an organoid comprising human cochlear hair cells generated by the methods described herein. For example, human cochlear hair cells are generated by (a) culturing PAX2 derived from human pluripotent stem cells in a medium comprising an activator of sonic hedgehog + Ear progenitor cells for at least 3 to 5 days; and (b) subsequently culturing the cells of step (a) in a culture medium comprising a sonic hedgehog activator and a Wnt inhibitor for a sufficient period of time to differentiate the cells into human cochlear hair cells expressing one or more of the following ear markers: GATA3 or NR2F1. The cochlear hair cells may express PRESTIN. The cells of step (b) may be further cultured in a culture medium without a SSH activator or a WNT inhibitor for at least 50 days, or at least 100 days, or at least 150 days, and the cochlear hair cells express two or more markers selected from PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3, and GNG8. The cochlear hair cells may express PRESTIN, NR2F1, GATA3, and INSM1. The cells may further express one or more of HES6, TMPRSS3, or GNG8. These cochlear hair cells can transmit hearing, see, for example, Figure 6d-6h .
[0065] The otic progenitor cells can be derived from pluripotent stem cells by the following method: (i) from day 0 to day 3, culturing the pluripotent stem cells in a medium containing FGF-2 and a TGF-β inhibitor (e.g., SB-431542) on a coated plate; (ii) from day 3 to day 7, culturing the cells of step (i) in a medium containing FGF-2, a TGF-β inhibitor, and a BMP-4 inhibitor (e.g., LDN 193189); (iii) from day 7 to day 11, culturing the cells of step (ii) in a medium containing a GSK-3 inhibitor (e.g., CHIR99021), a BMP-4 inhibitor; and (iv) from day 11 to day 18, culturing the cells of step (iii) in a medium containing a GSK-3 inhibitor on a coated plate to produce PAX + Ear progenitor cells.
[0066] Kits, Platforms, and Systems
[0067] In one aspect of the present disclosure, kits, systems and platforms are provided. The kits, systems or platforms may include one or more of the following: sonic hedgehog activators, Wnt inhibitors, FGF-2, TGF-β inhibitors, BMP-4 inhibitors, GSK-3 inhibitors, thyroxine and induced pluripotent stem cells or embryonic stem cells. The kits, systems or platforms may also include solid supports, laminin, nestin, vitronectin, fibronectin, collagen, Matrigel TM or a combination thereof.
[0068] Hybrid
[0069] Unless otherwise specified or the context indicates otherwise, the terms "a", "an" and "the" mean "one or more". For example, "a molecule" should be interpreted as "one or more molecules".
[0070] As used herein, "about," "approximately," "substantially," and "significantly" will be understood by one of ordinary skill in the art and will vary to some extent depending on the context in which the term is used. If the term is unclear to one of ordinary skill in the art in the context in which it is used, "about" and "approximately" will mean plus or minus 10% of the particular term, and "substantially" and "significantly" will mean plus or minus >10% of the particular term.
[0071] As used herein, the terms "include" and "including" have the same meaning as the terms "comprise" and "comprising." The terms "include" and "comprising" should be interpreted as "open" transition terms, which allow the inclusion of additional components other than those listed in the claims. The terms "consisting of" and "consisting of..." should be interpreted as "closed" transition terms, which do not allow the inclusion of other components other than those described in the claims. The term "consisting essentially of..." should be interpreted as partially closed, only allowing the inclusion of additional components that do not fundamentally change the claimed subject matter.
[0072] Unless otherwise specified herein or clearly contradictory to the context, all methods described herein can be performed in any suitable order. Any and all embodiments / examples provided herein, or the use of exemplary language (e.g., "for example / such as / such as") are merely to better illustrate the present invention, rather than to limit the scope of protection claimed by the present invention, unless otherwise indicated. All language in the specification should not be interpreted as indicating non-claimed elements that are necessary for the practice of the present invention.
[0073] All references, including publications, patent applications, and patents, cited herein are hereby incorporated by reference to the same extent as if each reference were individually and specifically indicated to be incorporated by reference in its entirety.
[0074] The preferred aspects of the present invention are described herein, including the best mode known to the inventor for implementing the present invention. By reading the foregoing description, the variations of those preferred aspects will become apparent to those of ordinary skill in the art. The inventor expects that those of ordinary skill in the art will appropriately adopt such variations, and the inventor wishes to practice the present invention in a manner different from that specifically described herein. Therefore, the present invention includes all modifications and equivalents of the subject matter described in the appended claims as permitted by applicable law. In addition, unless otherwise noted herein or clearly contradictory to the context, the present invention encompasses any combination of all possible variations of the above elements.
[0075] Example
[0076] Example 1 - Engineering high-fidelity cochlear organoids from human pluripotent stem cells
[0077] The human inner ear is one of the most complex organs in the body, with a snail-shaped cochlea and three orthogonal semicircular canals that contain the vestibular terminal organs. The former contains two different types of mechanosensitive hair cells (HCs) arranged in an orderly manner. The morphogenesis of the inner ear is coordinated by intertwined signaling events during fetal development. 1-3 The success rate of inner ear development during embryogenesis is over 99%. In fact, while nearly 10% of adults have moderate to severe hearing loss, the prevalence at birth is less than 0.2%, meaning that the vast majority of sensorineural hearing loss is due to postnatal death or dysfunction of cells in the developing primitive inner ear. 4 .
[0078] To reproduce the complex process of human inner ear development in vitro, the inventors previously established a defined 3D culture system to generate inner ear sensory epithelial cells from aggregates of mouse or human pluripotent stem cells. 5-8 . These so-called "inner ear organoids" carry a layer of supporting cells and functional hair cells, which are innervated by sensory-like neurons. However, these organoids consistently generate hair cells with structural, biochemical and functional properties comparable to native vestibular hair cells, but fail to generate any cochlear cell types. In order to more correctly mimic human inner ear development, the inventors aimed to create new organoid systems that contain the two types of mechanosensitive hair cells in the cochlea, outer hair cells and inner hair cells, which are essential for the correct detection of auditory stimuli.
[0079] result
[0080] Multiplex reporter hESC lines offer enhanced culture optimization
[0081] To monitor the derivation of middle ear progenitor cells and hair cells in culture and to improve upon the inventors' previously published protocol 5,8 To improve the efficiency of the culture, the inventors used CRISPR / Cas9 genome engineering to generate a PAX2-2A-nGFP / POU4F3-2A-ntdTomato reporter human embryonic stem cell (hESC) line. PAX2 is an early marker of otic progenitor cells in vivo, while the expression of POU4F3 is highly specific for hair cells and provides a late readout of culture efficiency. The inventors first demonstrated that PAX2b is the most abundantly expressed PAX2 isoform in human inner ear organoids ( Figure 8a -b). Use high-fidelity Cas9 9 Using an sgRNA targeting the stop codon of this isoform, the inventors knocked in a 2A-nGFP cassette immediately downstream of the endogenous PAX2 coding sequence. Similarly, using the established PAX2-2A-nGFP hESCs as the parental cell line, the 2A-ntdTomato cassette was knocked into the POU4F3 locus downstream of the POU4F3 stop codon ( Figure 1a -b). The resulting multi-reporter cell line uses nuclear GFP to label PAX2+ ear progenitor cells starting from around day 12 (D12) of organoid culture, and uses nuclear tdTomato to label POU4F3+ hair cells starting from around D35 (Figures 1c-m; Figures 8-9). Using the hESC reporter line that the inventors have established, the inventors systematically changed the basal culture medium, the timing and duration of small molecule treatment to optimize ear induction (Figure 2). In addition, although all ear lineage differentiations require BMP signaling to establish non-neural ectoderm, the inventors found that the inventors' cochlear organoid cultures are particularly sensitive to this parameter for achieving efficient ear induction and subsequent hair cell generation (Figure 10). After optimization, compared with the inventors' previous scheme 8,10 , the number of aggregates that produced hair cells more than doubled, and the number of hair cells per aggregate increased 20-fold.
[0082] Ventralization of inner ear organoids by sequential regulation of the SHH and WNT pathways
[0083] During inner ear development, the cochlear structures derive from the most ventral region of the otic capsule, while the vestibular structures arise from the more dorsal otic region. 1. Our culture platform relies in part on self-guided differentiation and patterning, and, similar to previously reported inner ear organoid protocols, our optimized basal control (CTRL) culture system consistently generates hair cells of a vestibular phenotype. We hypothesize that, as in embryonic development, extrinsic signals from the otic vesicle may be required for cochlear induction. Sonic hedgehog (SHH), a signaling molecule secreted from the floor of the neural tube and underlying notochord, is essential for patterning of the ventral otic vesicle. SHH is necessary and sufficient for ventralization of the otic vesicle and formation of cochlear architecture in mice and chicks 11,12 A recent study confirmed these previous reports and demonstrated that SHH pathway activation leads to inhibition of cAMP-dependent protein kinase A (PKA), thereby reducing proteolytic processing of the SHH downstream target GLI3 and regulating the expression of ventral-related genes. 12 In contrast, WNT and BMP signaling pathways have been shown to play a role in inducing dorsal gene expression during inner ear development. 13,14 .
[0084] Based on these previous mouse genetic studies, the inventors hypothesized that timed activation of the SHH pathway, coupled with inhibition of PKA, BMP, and / or WNT signaling, might promote upregulation of ventral otic genes, leading to the generation of cochlear hair cells in long-term cultures ( Figure 3a To test this hypothesis, the inventors cultured hESC-derived aggregates in the presence of the small molecule SHH agonist purmorphamine (PUR) alone or in combination with inhibitors of BMP (LDN), WNT (IWP2), and PKA (H89) ( Figure 3a ). For the sake of brevity, the permutations presented here are not exhaustive and include the results of SHH activation alone (PUR) or in combination with WNT inhibition (PUR+IWP2).
[0085] The inventors performed high-throughput single-cell RNA sequencing (scRNA-seq) analysis on D20 PAX2-nGFP+ sorted cells from aggregates generated under CTRL, PUR, or PUR+IWP2 conditions. Each condition was analyzed separately, with one batch per condition. A total of 37,073 cells were collected, and the batches were combined and clustered together. Unbiased clustering implemented in Seurat v3.2 showed that EPCAM / FBXO2+ otic progenitors from the PUR+IWP2 condition formed a unique cluster, while PUR and CTRL otic progenitors clustered together ( Figure 3b; Figure 11). Isolation of otic progenitors from all three conditions and subsequent differential expression analysis between conditions revealed that dorsal otic markers (such as DLX5, MSX1, GPR166, and ACSL4) were primarily restricted to PUR and CTRL treated cells, whereas ventral otic markers including OTX1 / 2, NR2F1 / 2, EDN3, and RSPO3 were concentrated in the PUR+IWP2 condition. In addition, genes involved in the SHH pathway (such as SULF1, LRP2, GAS1, and PTCH1) were highly expressed in PUR+IWP2 treated cells, but their expression was attenuated in CTRL and PUR treated progenitors ( Figure 3c ). In line with this, gene set enrichment analysis (GSEA) 15 The results showed that compared with untreated CTRL ear progenitor cells, the gene set associated with the Hedgehog pathway was enriched in the PUR+IWP2-treated ear progenitor cells, while the gene set associated with the canonical WNT pathway was downregulated. In addition, the analysis of PUR+IWP2-treated ear progenitor cells revealed multiple enriched gene sets for post-transcriptional regulation of gene expression, chromatin modification, and gene sets containing targets of known hereditary deafness genes encoding transcription factors, such as ZNF711, MORC2, GCM2, and BARHL1 ( Figure 3d ).
[0086] The inventors confirmed the scRNA-seq data using D25 organoids by immunofluorescence for NR2F1, SULF1, and OTX2 ( Figure 3e ; Figure 11). The inventors concluded that the more efficient ventralization of hESC-derived otic progenitors following sequential treatment with PUR and IWP2 is at least in part due to the regulation of SHH downstream gene targets. The inventors investigated the effects of the small molecule H89, a cell-permeable PKA inhibitor, alone or in combination with PUR and IWP2, but these treatments failed to effectively derive hair cells (Figure 12).
[0087] Otic progenitor cells generate cochlear hair cells in ventralized inner ear organoids
[0088] Starting from D22, PUR+IWP2-treated and CTRL aggregates were grown in defined medium without exogenous signaling molecules or growth factors. To compare the transcriptional profiles of PUR+IWP2-treated and CTRL HCs, D80 and -109 POU4F3-ntdT+ sorted cells were analyzed by scRNA-seq. The inventors adopted a non-stringent FACS gating strategy to collect cells with high and low expression of POU4F3, which resulted in the recovery of sequence data from 3,332 hair cells (18.9% of a total of 17,668 cells) and 4,582 hair cells (28.6% of a total of 16,044 cells) from the D80 and -109 samples, respectively. Similar to the D20 scRNA-seq data, when unbiased clustering of PUR+IWP2 hair cells was performed, the PUR+IWP2 hair cells were separated from the CTRL hair cells ( Figure 4a -b; Figures 13-14). Volcano plot showing differentially expressed genes between the two conditions identifies several known cochlear hair cell markers 16-19 , including GATA3, INSM1, HES6, TMPRSS3, and GNG8, whose expression in PUR+IWP2-treated hair cells was significantly higher than that in CTRL hair cells at D109 ( Figure 4c GSEA of PUR+IWP2 and CTRL hair cells showed that gene sets related to voltage-gated cation channel activity were upregulated in PUR+IWP2 hair cells, whereas genes related to cilia and microtubules were upregulated in CTRL hair cells (Figure 14).
[0089] Consistent with our scRNA-seq data, immunofluorescence of PUR+IWP2-treated organoids showed that POU4F3+ cells expressed significantly higher levels of cochlear hair cell marker proteins such as NR2F1 and GATA3 ( Figure 4e -f), which was confirmed in the hair cells of the fetal human cochlea at gestational week (GW) 18 ( Figure 4g ).
[0090] Scanning electron microscopy was performed to compare the structural properties of hair bundles on the apical surface of derived hair cells between PUR+IWP2 and CTRL organoids (Figure 5a-h). The structural development of hair bundles was observed in organoid hair cells - from the appearance of kinocilium in the middle of the cuticular plate to the development of stereocilia in a step-like pattern. 20, which is commonly seen in the mouse inner ear (Figure 15). The inventors also detected tip-link-like structures between individual stereocilia (Figure 15). These transitional characteristics reproduce the development of mouse cochlear hair bundles. In CTRL organoids at D110-200, the inventors continued to observe long and pointed hair bundle arrangements, which are characteristic of vestibular hair cells. In sharp contrast, in PUR+IWP2-treated samples, the length of the hair bundles was significantly shorter, and the stereocilia were generally arranged in linear or concave geometries, similar to the stereocilia on the apical surface of inner hair cells in the mouse cochlea (Figures 5a-h; Figure 15). High-resolution confocal microscopy confirmed these results, showing differences in the arrangement and total length of stereocilia between PUR+IWP2-treated and untreated CTRL hair cells (Figures 5i-l). In addition, in the hair bundles treated with PUR+IWP2, the diameter and length of individual stereocilia were positively correlated. In contrast, the diameter of individual CTRL stereocilia was consistent across their different lengths (Fig. 5m; Fig. 15). These structural differences in hair bundles between PUR+IWP2 and control hair cells are consistent with the structural differences observed between cochlear and vestibular hair cells in the mammalian inner ear.
[0091] To assess the identity of PUR+IWP2-treated hair cells, the inventors examined PRESTIN 21 The expression of PRESTIN was characteristic of cochlear outer hair cells. Membrane-localized PRESTIN was detected in some samples as early as D102 (0.33% of HCs), and its expression became more widespread with increasing culture age. On days 150 and 200, 12.6% and 16.8% of all PUR+IWP2-treated hair cells expressed membrane-localized PRESTIN, respectively. Figure 6a -b). In contrast, PRESTIN was not detected in any CTRL hair cells until D200 ( Figure 6a To assess the functional development of hESC-derived hair cells, we performed conventional whole-cell patch clamp recordings of voltage-activated ionic conductances in cells expressing a strong tdTomato reporter ( Figure 6c ). Using K-based + The intracellular solution of the cells identified two functionally distinct cell types. The first group of cells (type A) was observed to be more numerous (78%) and was characterized by a fast outward current and almost no inward current ( Figure 6d , f), similar to mature cochlear outer hair cells 22 A smaller number (22%) of cells (type B) showed a slow outward current ( Figure 6e , h) and a significant fast inward current ( Figure 6g ), and K in immature inner hair cells + and Na + Current Similarity22 Both cell types had similar reversal potentials (mean = -34.7 mV, range -17.5 to -55.5 mV), and there was no evidence of KCNQ-type fast K + Current is activated at resting potential 22 .
[0092] Previous studies have shown that thyroid hormone is essential for hair cell maturation and that postnatal thyroxine replacement rescues the inner ear phenotype of PAX8-null mice 31 In addition, thyroid hormone has been shown to directly regulate the expression of PRESTIN through the thyroxine response element in the promoter region of slc26a5 32 The inventors speculate that the delayed onset of PRESTIN expression and incomplete HC maturation in the inventors' cochlear organoid cultures may be due, at least in part, to hypothyroid culture conditions. From culture day 50 (around the first appearance of HCs in cochlear cultures) until D100, the number of PRESTIN+HCs in cultures treated with 250 ng / mL T4 was much greater than that in cultures without supplementation at D100 or even D150 (approximately 80% vs. approximately 1% vs. approximately 13%) ( Figure 6a , Figure 7a,b). In addition, SOX2 expression was also downregulated in T4-treated HCs (Figure 7c), but not in supporting cells or unsupplemented HCs, suggesting that thyroid hormone signaling is also required for maturation of cochlear organoid cultures.
[0093] discuss
[0094] Existing inner ear organoid generation protocols only produce hair cells with similar structural, molecular and physiological properties to native vestibular hair cells. On the other hand, this experimental example demonstrates the development of a method to derive cochlear hair cell types in organoids. Since the gradient SHH concentration along the dorsoventral axis of the otic capsule is considered to be the main ventralization cue during inner ear development, the inventors first studied the effect of the potent smoothened agonist PUR on changes in gene expression in D20 organoids. Enhancing the SHH pathway alone is not sufficient to promote the expression of ventral ear markers. To further strengthen the ventralization conditions, the inventors applied the PKA inhibitor H89, because previous reports have shown that PKA activity is a mediator of the SHH pathway. Although the combined treatment of PUR and H89 promoted the expression of ventral ear markers OTX2 and GATA3, this treatment greatly reduced the efficiency of deriving POU4F3+ hair cells, forcing the inventors to abandon this approach. At the same time, the inventors began to co-treat hESC-derived aggregates with the WNT inhibitor IWP2 five days after treatment with PUR. This treatment resulted in a significant upregulation of ventral ear markers while suppressing dorsal ear markers. The inventors also observed significant upregulation of SHH downstream effectors (such as SULF1, LRP2, GAS1 and PTCH1) in PUR+IWP2-treated samples, but not in CTLR or PUR-treated samples, suggesting that ventralization of otic progenitor cells requires threshold SHH pathway activation, including upregulation of downstream effectors of ligand receptors and WNT signaling antagonism.
[0095] The inventors' scRNA-seq analysis of D80 and -109 samples showed that PUR+IWP2-treated hair cells and untreated control hair cells exhibited different transcriptional profiles. Among the genes differentially expressed between the two cell populations, NR2F1 and GATA3 were most highly expressed in PUR+IWP2-treated hair cells at D80 and -109, suggesting that these two genes may be potential candidates for core elements in the transcriptional pathway leading to cochlear differentiation. GATA3 has been shown to be primarily expressed in cochlear tissue compared to vestibular tissue. 23,24 Targeted inactivation of NR2F1 leads to the appearance of extra hair cells and supporting cells in the developing mouse cochlea, which is associated with dysregulation of Notch signaling components. 25 NR2F1 / 2 are thought to function as ligand-dependent transcription factors and thus serve as master drivers that confer the ability of multipotent otic progenitor cells to differentiate into cochlear cell types. However, of note, NR2F1 / 2 have been shown to play an important role in dorsal-ventral patterning of the optic vesicle through direct regulation of OTX2 expression. 26 .
[0096] The inventors attempted to further classify the hair cells derived from the ventralized inner ear organoids as either outer cochlear hair cells or inner cochlear hair cells. Structurally, these hair cells are U-shaped hair bundles with short stereocilia of varying diameters, which are common in the inner hair cells of the mammalian cochlea. 27,28 However, INSM1, a zinc finger transcription factor essential for outer hair cell differentiation in mice 29 TBX2, a pioneer factor in inner hair cell differentiation, was expressed primarily in hair cells of PUR+IWP2-treated organoids, whereas TBX2, a pioneer factor in inner hair cell differentiation, was expressed primarily in hair cells of PUR+IWP2-treated organoids. 30 There was no significant difference in the expression of . In addition, the inventors' electrophysiological recordings identified two different populations of hair cells in D138-164 PUR+IWP2 organoids. About 78% of these hair cells were characterized by fast outward currents and almost no inward currents, which is similar to the native outer hair cells in the mouse cochlea, but different from the inner hair cells. This seems to contradict the observation that the proportion of hair cells expressing the outer hair cell marker PRESTIN is low. The scRNA-seq results at D109 showed that only 1.6% of PUR+IWP2 hair cells expressed SLC26A5 encoding PRESTIN, and only 6.4% of these hair cells expressed SLC17A8 encoding the inner hair cell marker VGLUT3. 31 Since PRESTIN + The proportion of hair cells increased over time from D102 to 200 (from 0.33% to 16.8%), and our results collectively suggest that many of the derived hair cells have not reached full phenotypic maturity when scRNA-seq experiments were performed.
[0097] Based on the inventors' transcriptional and structural analyses, the time course of hESC-derived cochlear organoid development is very similar to that of the human cochlea, with D110 cochlear organoids roughly corresponding to the human fetal cochlea at GW18 (Figure 16). In addition, the order of marker expression was faithfully reproduced in the cochlear organoids, with ATOH1 expression preceding MYO7A expression. In the outer hair cells of the human fetal cochlea, PRESTIN was detected at GW18 but not at GW13. Similarly, in PUR+IWP2-treated organoids, PRESTIN was detected in approximately 16% of the hair cells at D200, but was almost undetectable at D102. These results indicate that the cochlear organoids established by the inventors in this study can reach a developmental stage comparable to that of the human cochlea in the third trimester.
[0098] The inventors have demonstrated that regulation of the SHH and WNT pathways confers a ventral ear phenotype to multipotent otic progenitor cells, some of which subsequently generate hair cells with structural, transcriptional, and functional properties of two types of cochlear hair cells (inner and outer hair cells) and mature in vitro to a stage corresponding to the third trimester of human fetal development. In addition, scRNA-seq analysis also identified NR2F1 as a previously unrecognized candidate in a key transcriptional pathway required for cochlear and vestibular diversification. Further studies are needed to elucidate the potential cross-talk mechanisms between transcriptional pathways and structural development and to establish methods to control the generation of inner and outer hair cells. The cochlear organoids established by the inventors in this study are expected to become a powerful human model for studying the biological characteristics of human cochlear development, elucidating the pathogenesis of inherited hearing loss, and identifying therapeutic targets for the treatment of severe hearing loss.
[0099] Materials and methods
[0100] Establishment of PAX2 / POU4F3 reporter hESC line using CRISPR / Cas9
[0101] To monitor the derivation of middle ear progenitor cells in 3D culture, the inventors generated a PAX2 reporter hESC line by integrating a 2A-eGFP-nls (2A-nGFP) fluorescent reporter at the endogenous PAX2 locus using CRISPR / Cas9 genome engineering technology. Based on the location of the stop codon, PAX2 splice variants can be divided into PAX2b, PAX2c, and PAX2d types. 32-34 . A cDNA library from D40 human inner ear organoids and PAX2b, PAX2c, and PAX2d synthetic cDNA gBlocks (IDT) for size reference were PCR amplified. Agarose gel electrophoresis of PCR amplicons followed by Sanger sequencing verification of the extracted brightest bands showed that PAX2b is the most abundant PAX2 isoform in human inner ear organoids. Therefore, gRNAs and homology arms were designed to target the PAX2b stop codon locus. To construct the PAX2-2A-eGFP-nls-pA-loxP-PGK-Puro-pA-loxP donor vector, two 1 kb homology arms flanking the PAX2b stop codon were PCR amplified from WA25 hESC (WiCell) genomic DNA. Gibson assembly 35 For binding of two homology arms to 2A-eGFP 8,36 , nls-stop-bGH polyA (gBlock, IDT) and loxP-PGK-Puro-pA-loxP DNA fragments 8,36The linearized pUC19 plasmid backbone was ligated into the final donor vector. The gRNA targeting the PAX2b stop codon (5'-ATGACCGCCACTAGTTACCG-3' (SEQ ID NO: 29)) was cloned into the expression plasmid under the control of the U6 promoter (Addgene #71814) 37 The PAX2-2A-nGFP donor vector, PAX2b gRNA plasmid, and high-fidelity Cas9 expression plasmid (SpCas9-HF1, Advantgene #72247) were transfected with 4D Nucleofector (Lonza) using the P3 primary cell 4D-NucleofectorX kit and program CB-150. 9 After nucleofection, cells were plated in E8fn medium containing 1× RevitaCell (Thermo Fisher Scientific) to improve cell survival, and the medium contained 1 μM Scr7 (Xcessbio) to improve HDR efficiency 38 . Starting 48 hours after nucleofection, 0.5 μg / mL puromycin selection was performed for 14 days. After puromycin selection by nucleofection of a Cre recombinase expression vector (Adgene #13775), the PGK-Puro subcassette flanked by two loxP sites was removed from the genome. The cells were plated at low density (1-3 cells / cm 2 ) to establish a clonal cell line, and then isolate hESC clones after 5-7 days of amplification. Gel electrophoresis is then performed by PCR amplification, and the genotype of the clonal cell line is analyzed by Sanger sequencing of the total PCR amplicon or a single PCR amplicon cloned into a TOPO vector (Thermo Fisher). Cell lines with biallelic 2A-nGFP integration are used for subsequent experiments. The first 10 predicted gRNA off-target sites were PCR amplified (about 1kb) from the genomic DNA of the established cell line, and Sanger sequencing was performed to test off-target mutations.
[0102] To construct the PAX2-2A-nGFP / POU4F3-2A-ntdTomato multiplex reporter cell line, POU4F3-2A-ntdTomato knock-in CRISPR was performed in the PAX2-2A-nGFP genetic background. The POU4F3-2A-tdTomato-nls-bGH polyA-frt-PGK-Puro-pA-frt donor plasmid was constructed by Gibson assembly of the following DNA fragments: two 1 kb homology arms flanking the POU4F3 stop codon amplified from WA25 genomic DNA, 2A-tdTomato gBlock DNA, nls-stop-bGHpA gBlock DNA, frt-PGK-Puro-frt gBlock DNA (IDT), and a linearized pUC19 backbone. The completed donor plasmid was transfected into the PAX2-2A-nGFP parental hES cell line along with a ribonucleoprotein complex consisting of a synthetic sgRNA (5'-ATTCGGCTGTCCACTGATTG-3' (SEQ ID NO: 30)) (Synthego), targeting the POU4F3 stop codon locus, and a high-fidelity Cas9 protein (HiFi Cas9 v3, IDT). Transfection was also performed using a 4D Nucleofector (Lonsa), using the P3 primary cell 4D-Nucleofector X kit and program CB-150. After nuclear transfection, the cells were seeded in E8fn medium containing 1×RevitaCell (Thermo Fisher Scientific) and 1 μM Scr7 (Xcessbio). Starting 48 hours after nuclear transfection, 0.5 μg / mL puromycin selection was performed for 9 days. The frt-flanked PGK-Puro cassette was removed by FLPo transfection (Adgene #13793). The clonal cell line isolation and genotyping procedures were the same as for PAX2-2A-nGFP CRISPR. The final multiplex cell line selected for downstream experiments had a biallelic 2A-nGFP knock-in at the PAX2 locus and a biallelic 2A-ntdTomato knock-in at the POU4F3 locus, and was karyotyped by KaryoLogic Inc. (Research Triangle Park, North Carolina).
[0103] Organoid culture
[0104] PAX2-2A-nGFP / POU4F3-2A-ntdTomat hESCs (passages 22-50) were cultured and passaged in Essential 8Flex medium (Thermo Fisher, A2858501) supplemented with 100 μg / ml Normocin (E8fn) on 6-well plates coated with recombinant human vitronectin-N (Thermo Fisher, A14700). ,10 After major modifications, human inner ear organoids were derived from hESCs. Briefly, hESCs were dissociated with StemPro Accutase (Thermo Fisher, A1110501) and plated at 3500 cells / well in a low-adhesion 96-well U-bottom plate in 100 μL E8fn containing 20 μM Y-27632 (Stemgent, 04-0012-02) and forced to aggregate at 120 g for 5 minutes. After incubation for >4 hours, 100 μL E8fn was added to each well. Non-neural epithelial induction was performed 48 h after aggregation, marked as differentiation day 0, as follows: the aggregates were thoroughly washed in DMEM:F12 containing HEPES buffer (DFH) (Thermo Fisher, 11320033) and then transferred to a new 96-well U-bottom plate in 100 μL E6 medium (Thermo Fisher, A1516401) containing Normocin (E6n) containing 4 ng mL -1FGF-2 (StemCell Technologies, 780003), 10 μM SB-431542 (Stemgent, 04-0010-05) and 2% growth factor reduced (GFR) Matrigel (Corning, 354230). On the 3rd day of differentiation, 25 μL of E6n containing 50 ng / mL FGF-2 and 200 nM LDN-193189 (Stemgent, 04-0074-02) was added to each well. On the 7th and 9th days, the medium was replaced with E6n containing 3 μM CHIR 99021 (Reprocell, 04-0004-10), 200 nM LDN and 50 ng / mL FGF-2. On day 11, aggregates were washed and transferred to organoid maturation medium (OMM) in Nunc Delta surface 6-well culture plates containing 1% GFR Matrigel and 3 μM CHIR99021. OMM consisted of a 50:50 mixture of Advanced DMEM:F12 (Thermo Fisher, 12634028) and Neurobasal medium (Thermo Fisher, 21103049) supplemented with 0.5×N2 supplement (Thermo Fisher, 17502048), 0.5×B27 minus vitamin A (Thermo Fisher, 12587010), 1×GlutaMAX (Thermo Fisher, 35050061), 0.1 mM β-mercaptoethanol (Thermo Fisher, 21985023) and Normocin. Control cultures were maintained in OMM + 3 μM CHIR99021 medium until day 18, with medium changes on days 13 and 15, and then OMM medium was used for the rest of the time. Treatment cultures were supplemented with 1 μM purmorphamine (Stemgent, 04-0009) on days 13-22, IWP-2 (Tocris, 3533) on days 18-22, with medium changes on days 15, 18, and 20, and then maintained in OMM for the rest of the culture period.
[0105] Immunohistochemistry
[0106] Aggregates were fixed with 4% paraformaldehyde for 30 minutes at room temperature or overnight at 4°C. Fixed specimens were cryoprotected with graded series sucrose and then embedded in tissue freezing medium. Frozen tissue blocks were cut into 12 μm cryosections on a Leica CM-1860 cryostat. For immunostaining, 10% goat or horse serum in 0.1% Triton X-100 1× PBS solution was used for blocking, and 3% goat or horse serum in 0.1-1% Triton X-100 1× PBS solution was used for primary / secondary antibody incubation. The primary antibodies used in this study are listed in Table 1. Alexa Fluor-conjugated anti-mouse, rabbit or goat IgG (Thermo Fisher) was used as a secondary antibody. Samples were sealed and cell nuclei were visualized using ProLong Gold antiquencher (containing DAPI) (Thermo Fisher).
[0107] AbScale tissue-clearing protocol for whole-mount immunofluorescence 39 Apply to aggregated samples. Unless otherwise stated, incubation and washing steps are performed on a rotor, and incubation steps are performed on a rotor at 37°C. After fixing the samples with 4% paraformaldehyde overnight, the samples were incubated in Scale S0 solution for 6 hours, followed by incubation in Scale A2 solution for 16 hours, incubation in ScaleB4 solution for 24 hours, and incubation in ScaleA2 solution for 8 hours. Thereafter, the samples were incubated at room temperature for 4 hours in 0.1M PBS and blocked with 10% normal horse serum (Vector Laboratories) in AbScale solution for 16 hours. Incubate in primary antibody in AbScale solution containing 3% normal horse serum for 48 hours, then wash sequentially with AbScale solution for 15, 30, 60 and 120 minutes, and incubate with fluorophore-coupled secondary antibody in AbScale solution containing 3% normal horse serum for 24 hours. After rinsing with AbScale three times for 30 minutes at room temperature and 2 times for 30 minutes with AbScale rinse solution at room temperature, the samples were then refixed with 4% paraformaldehyde for 1 hour at room temperature, washed twice with 0.1M PBS, and incubated in ScaleS4 solution for 16 hours. The stained samples were mounted on coverslips coated with poly-L-ornithine with silicone gaskets (Fisher Scientific) using a small amount of ScaleS4 solution. Samples were imaged on a Leica Dive confocal / multiphoton microscope or a Nikon A1RHD25 confocal microscope. Three-dimensional reconstructions were performed using the Imaris 8 software package (Bitplane) and NIS Elements advanced research application software (Nikon).
[0108] Quantification of immunohistochemical data
[0109] Treated and control samples were processed for immunostaining simultaneously using the same reagents and protocols for each comparison. Images were acquired using a Nikon A1R-HD25 confocal microscope or a Leica DMI8 widefield fluorescence microscope, using identical image acquisition parameters between conditions. Raw images were analyzed using the Nikon GI3 suite or exported in TIFF format and analyzed using ImageJ. Co-expression analysis was performed by analyzing areas of consistent signal corresponding to labeled tissue-specific markers and genes of interest. Mean grayscale values and total localization area were collected.
[0110] Statistical analysis was performed using Graphpad Prism 9. All data were analyzed using two-sided Welch's T test. Data collection and analysis were not blinded.
[0111] Scanning electron microscopy
[0112] Aggregates with abundant POU4F3-ntdTomato+ spots between differentiated D81 and 141 were fixed overnight at 4°C with 2.5% glutaraldehyde in sodium cacodylate buffer (Electron Microscopy Sciences). Fixed samples were dissected under a Nikon SMZ18 stereofluorescence microscope to expose the luminal surface of vesicles containing ntdTomato+ cells and post-fixed with 1% osmium tetroxide (Electron Microscopy Sciences) at room temperature for 1 hour. The samples were then dehydrated through a graded series of ethanol and transferred to a Leica EM CPD300 critical point dryer. After critical point drying, the samples were mounted on aluminum rods and sputtered using a Denton Vacuum Desk V sample preparation system. The samples were observed at an accelerating voltage of 5kV on a JEOL JSM-7800F field emission scanning electron microscope.
[0113] Representative Data and Reproducibility
[0114] Unless otherwise stated, images are representative of specimens obtained from at least three separate experiments. For immunohistochemical analysis of aggregates, the inventors typically excised 6-15 aggregates from each condition in each experiment.
[0115] scRNA-seq and raw data processing
[0116] Isolation of PAX2 nG +(D20 sample) or POU4F3 nT+ (D80 and -109 samples) cells and used for scRNA-seq analysis. 30 to 45 aggregates / condition were washed with 0.5mM EDTA (Thermo Fisher) in DPBS, and then incubated on an orbital shaker at 37 ° C for 30 minutes with 1.1mM EDTA in 1XTrypLE (Life Technologies) in DPBS, followed by incubation without shaking for 40-50 minutes. During the incubation period, the samples were mechanically dissociated by oscillation on a Nunclon Sphera 24-well plate (Thermo Fisher), and occasionally gently blown with a P1000 pipette tip. After confirming that most cells, especially cells with reporter expression, were completely dissociated, they were filtered through 100-μm and 40-μm cell strainers (Falcon) in turn, and then transferred to 2ml tubes (Eppendorf). After centrifugation at 100 × g for 5 minutes, the dissociated cells were resuspended in a FACS buffer consisting of 2% fetal bovine serum (Thermo Fisher) in 1X DPBS. The cells were filtered through a 40-μm cell strainer again and collected in a 5-ml round-bottom polypropylene tube (Falcon). Dead cells were stained with propidium iodide (PI, Invitrogen) diluted 1:500. At the same time, using the above protocol, size control cells not stained with PI were prepared using aggregates made from wild-type hESC. The cells were kept on ice and protected from light before sorting. SORP Aria (BD Biosciences) was used to collect and clean PI negative and GFP (or tdTomato) positive populations.
[0117] cDNA libraries were constructed using the 10X Genomics Chromium 3'v3 platform and sequenced using the NovaSeq 6000 system (Illumina), and scRNA-seq was performed on all samples. For each sample, 12,000 to 18,000 cells were added to the single cell master mix according to the ChromiumNextGEM Single Cell 3' reagent kit user guide. The single cell master mix was dispensed onto the single cell chip G along with the single cell gel beads and the dispense oil, and the chip was loaded into the Chromium controller for barcoding and cDNA synthesis. The resulting cDNA library was sequenced using the NovaSeq 6000 system, which ran a custom program for 28-bp plus 91-bp double-end sequencing, resulting in a read depth of more than 40,000 reads / cell.
[0118] BCL files were generated using Illumina's CellRanger v4.0.0 program, de-mutiplexed and converted to FASTQ files using bcl2fastq conversion software (Illumina). FASTQ files were then aligned to the GRCh38-3.0.0 reference genome using the STAR (spliced transcript alignment with reference) aligner. Mapped reads were grouped by cell barcode, single-cell gene expression was quantified using unique molecular identifiers (UMIs), and the resulting filtered gene barcode (count) matrix was used as input for downstream analysis.
[0119] scRNA-seq data analysis
[0120] The filtered count matrices were preprocessed for each dataset individually, removing cells with mitochondrial gene counts exceeding 12.5% of the total number of molecules detected. A second preprocessing step removed cells with aberrant housekeeping gene expression: cells with log-transformed RPL27 expression ±2 standard deviations from the mean were removed. After preprocessing, datasets were merged across conditions to generate a combined dataset for each time point. After merging, the datasets were analyzed using Seurat 40 The SCTransform function in the was used to normalize the gene expression levels and convert the raw count data into Pearson residuals, effectively controlling the technical variation caused by heterogeneous sequencing depth. Using Seurat's unsupervised clustering workflow, more than 50 different cluster partitions were generated by changing the resolution and k.param parameter values required for clustering and shared nearest neighbor graph construction, respectively. Then, the cluster partition with the highest silhouette index was selected for further analysis. 41 . Cluster identities were manually determined based on the expression of classical markers.
[0121] Related populations (e.g., otic progenitors, hair cells) were separated based on cluster identity and analyzed using DESeq2 and zingeR 42 Comparisons between treatment groups were performed. Cell-level weights were calculated using zingeR (adjusted for drop-out events specific to scRNA sequencing). Differential expression between treatment groups was determined using DESeq2, and genes with Benjamini-Hochberg P < 0.05 were considered statistically significant. The results of DESeq2 analysis were passed to the gene set enrichment analysis platform iDEA 15 The differentially expressed genes were compared with those from the MSigDB database 43 The Gene Transcription Regulation Database (GTRD) was used to define a set of 573 transcription factor target genes, with which the inventors' data were compared. 44Although these gene sets are well defined, they do not constitute an exhaustive list of all possible transcription factors.
[0122] Electrophysiological analysis
[0123] D138-164 hESC-derived organoids were first imaged in bright field and epifluorescence illumination (TE2000-U, Nikon) to determine the localization of the otic capsule with tdTomato-positive cells. Then, the organoids were sliced with a diamond knife to expose the otic capsule. The slices were placed in a custom-made recording chamber and fixed by two strands of dental floss. Recordings were performed at room temperature (20-25°C) in Leibovitz's L-15 cell culture medium (Catalog No. 21083027, Gibco / Thermo Fisher Scientific, USA), containing the following inorganic salts (in mM): NaCl (137), KCl (5.4), CaCl2 (1.26), MgCl2 (1.0), Na2HPO4 (1.0), KH2PO4 (0.44), MgSO4 (0.81). Cells were observed using an upright microscope (E600FN, Nikon) equipped with a high numerical aperture (NA) objective (60x, 1.0NA) and an epifluorescence attachment. Only cells with bright tdTomato signals were selected for recording. During recording, organoid slices were continuously perfused with L-15 medium. Pipettes for whole-cell patch clamp recordings were filled with an intracellular solution containing (in mM): KCl (12.6), KGlu (131.4), MgCl2 (2), EGTA (0.5), K2HPO4 (8), KH2PO4 (2), Mg2-ATP (2), and Na4-GTP (0.2). The solution was adjusted to pH 7.3-7.4 with KOH and to 320 mOsm with D-glucose. The uncompensated pipette resistance was typically 5-8 MOhm when measured in a bath. Whole-cell current responses were recorded using a MultiClamp 700B patch clamp amplifier controlled by pClamp software (Molecular Devices, USA).
[0124] Human tissue ethics, collection, and immunofluorescence
[0125] Human fetal cochleae were collected and processed at Leiden University Medical Center (The Netherlands) from tissue obtained from elective abortions using vacuum aspiration. Prior to surgery, obstetric ultrasound examinations were performed to determine gestational age (GW) and days. One cochlea from GW 13 and another from GW 18 were used in this study. Fresh samples were collected in PBS, fixed in 4% paraformaldehyde in PBS overnight at 4°C, decalcified, and embedded in paraffin as previously described.45 . Paraffin blocks were cut into 5-μm-thick sections through the sagittal plane using a Leica rotary microtome. Serial sections were dewaxed in xylene, rehydrated in a decreasing ethanol series (100%, 90%, 70%, 50%), and rinsed in distilled water. Thereafter, sections were treated in 0.01 M sodium citrate buffer (pH 6.0) at 98°C for 12 min using a boiling pot for antigen retrieval and then processed for immunofluorescence. The primary antibodies used in this study are listed in Table 1. Stained samples were observed and imaged on a Zeiss LSM900 confocal microscope. The use of human fetal tissue was approved by the Medical Ethics Committee of the Leiden University Medical Center (protocol number 08.087). Informed written consent was obtained in accordance with the guidelines of the World Medical Association's Declaration of Helsinki.
[0126] Table 1. Antibodies used in Example 1
[0127]
[0128]
[0129]
[0130] AF488, Alexa Fluor 488. AF594, Alexa Fluor 594. IHC, immunohistochemistry.
[0131] References
[0132] 1Barald, KF & Kelley, MW From placode to polarization: new tunes in inner ear development. Development 131, 4119-4130, doi: 10.1242 / dev.01339 (2004).
[0133] 2Groves, AK & Fekete, DM Shaping sound in space: the regulation of inner ear patterning. Development 139, 245-257, doi:10.1242 / dev.067074 (2012).
[0134] 3Wu, DK&Kelley, MW Molecular mechanisms of innerear development. Cold Spring Harb Perspect Biol 4, a008409, doi: 10.1101 / cshperspect.a008409 (2012).
[0135] 4Morton, CC & Nance, WE. Newborn hearing screening—a silent revolution. N Engl J Med 354, 2151-2164, doi: 10.1056 / NEJMra050700 (2006).
[0136] 5Koehler, KR, Mikosz, AM, Molosh, AI, Patel, D. & Hashino, E. Generation of inner ear sensory epithelia from pluripotent stem cells in 3D culture. Nature 500, 217-221, doi: 10.1038 / nature12298 (2013).
[0137] 6Koehler, KR & Hashino, E. 3D mouse embryonic stem cell culture for generating inner ear organoids. Nat Protoc 9, 1229-1244, doi: 10.1038 / nprot.2014.100 (2014).
[0138] 7Liu, XP, Koehler, KR, Mikosz, AM, Hashino, E. & Holt, JR. Functional development of mechanosensitive hair cells in stem cell-derived organoids parallels native vestibular hair cells. Nat Commun 7, 11508, doi: 10.1038 / ncomms11508 (2016).
[0139] 8Koehler, KR et al. Generation of inner ear organoids containing functional hair cells from human pluripotent stem cells. Nat Biotechnol 35, 583-589, doi: 10.1038 / nbt.3840 (2017).
[0140] 9Kleinstiver, BP et al. High-fidelity CRISPR-Cas9 nucleases with no detectable genome-wide off-target effects. Nature 529, 490-+, doi:10.1038 / nature16526 (2016).
[0141] 10Nie, J. & Hashino, E. Generation of innerear organoids from human pluripotent stem cells. Methods Cell Biol 159, 303-321, doi: 10.1016 / bs.mcb.2020.02.006 (2020).
[0142] 11Riccomagno, MM, Martinu, L., Mulheisen, M., Wu, DK & Epstein, DJ. Specification of the mammalian cochlea is dependent on Sonic hedgehog. Genes Dev 16, 2365-2378, doi: 10.1101 / gad.1013302 (2002).
[0143] 12Ohta, S., Wang, B., Mansour, SL & Schoenwolf, G.C. SHH ventralizes the otocyst by maintaining basal PKA activity and regulating GLI3 signaling. Dev Biol 420, 100-109, doi: 10.1016 / j.ydbio.2016.10.004 (2016).
[0144] 13Ohta, S., Wang, B., Mansour, SL & Schoenwolf, GCBMP regulates regional gene expression in the dorsal otocyst through canonical and non-canonical intracellular pathways. Development 143, 2228-2237, doi: 10.1242 / dev.137133 (2016).
[0145] 14Riccomagno, MM, Takada, S. & Epstein, DJ. Wnt-dependent regulation of inner ear morphogenesis is balanced by the opposing and supporting roles of Shh. Genes Dev 19, 1612-1623, doi:10.1101 / gad.1303905 (2005).
[0146] 15Ma, Y. et al. Integrative differential expression and gene set enrichment analysis using summary statistics for scRNA-seq studies. Nat Commun 11, 1585, doi: 10.1038 / s41467-020-15298-6 (2020).
[0147] 16Burns, JC, Kelly, MC, Hoa, M., Morell, RJ & Kelley, MW. Single-cell RNA-Seq resolves cellular complexity in sensory organs from the neonatal inner ear. Nat Commun 6, 8557, doi: 10.1038 / ncomms9557 (2015).
[0148] 17Scheffer, DI, Shen, J., Corey, DP & Chen, ZY. Gene Expression by Mouse Inner Ear Hair Cells during Development. J Neurosci 35, 6366-6380, doi: 10.1523 / JNEUROSCI.5126-14.2015 (2015).
[0149] 18Kolla, L. et al. Characterization of the development of the mouse cochlear epithelium at the single cell level. Nat Commun 11, 2389, doi: 10.1038 / s41467-020-16113-y (2020).
[0150] 19Elkon, R. et al. RFX transcription factors are essential for hearing in mice. Nat Commun 6, 8549, doi: 10.1038 / ncomms9549 (2015).
[0151] 20Barr-Gillespie, PG. Assembly of hair bundles, an amazing problem for cell biology. Mol Biol Cell 26, 2727-2732, doi: 10.1091 / mbc.E14-04-0940 (2015).
[0152] 21 Zheng, J. et al. Prestin is the motor protein of cochlear outer hair cells. Nature 405, 149-155, doi: 10.1038 / 35012009 (2000).
[0153] 22Ahmed, ZM et al. The tip-link antigen, a protein associated with the transduction complex of sensory hair cells, is protocadherin-15. J Neurosci 26, 7022-7034, doi: 10.1523 / JNEUROSCI.1163-06.2006 (2006).
[0154] 23Luo, XJ et al. GATA3 controls the specification of prosensory domain and neuronal survival in the mouse cochlea. Hum Mol Genet 22, 3609-3623, doi: 10.1093 / hmg / ddt212 (2013).
[0155] 24Bardhan, T. et al. Gata3 is required for the functional maturation of inner hair cells and their innervation in the mouse cochlea. J Physiol 597, 3389-3406, doi: 10.1113 / JP277997 (2019).
[0156] 25 Tang, LS, Alger, HM & Pereira, FA COUP-TFI controls Notch regulation of hair cell and support cell differentiation. Development 133, 3683-3693, doi: 10.1242 / dev.02536 (2006).
[0157] 26 Tang, K. et al. COUP-TFs regulate eye development by controlling factors essential for optic vesicle morphogenesis. Development 137, 725-734, doi: 10.1242 / dev.040568 (2010).
[0158] 27Velez-Ortega, AC, Freeman, MJ, Indzhykulian, AA, Grossheim, JM & Frolenkov, GI. Mechanotransduction current is essential for stability of the transducingstereocilia in mammalian auditory hair cells. Elife 6, doi: 10.7554 / eLife.24661 (2017).
[0159] 28Hadi, S., Alexander, AJ, Velez-Ortega, A.C. & Frolenkov, G.I. Myosin-XVa Controls Both Staircase Architecture and Diameter Gradation of Stereocilia Rows in the Auditory Hair Cell Bundles. J Assoc Res Otolaryngol 21, 121-135, doi:10.1007 / s10162-020-00745-4 (2020).
[0160] 29Wiwatpanit, T. et al. Trans-differentiation of outer hair cells into inner hair cells in the absence of INSM1. Nature 563, 691-695, doi:10.1038 / s41586-018-0570-8 (2018).
[0161] 30Garcia-Anoveros, J. et al. Tbx2 is a master regulator of inner versus outer hair cell differentiation. Nature 605, 298-303, doi: 10.1038 / s41586-022-04668-3 (2022).
[0162] 31Christ, Stephanie; Biebel, Ulrich W; Silvi Hoidis; Friedrichsen, Bauer, Karl; et al. Audiology & Neurotology; Basel, Vol. 9, No. 2, (March / April 2004): 88-106.
[0163] 32Weber T,Zimmermann U,Winter H,Mack A, I, Rohbock K, Zenner HP, Knipper M. Thyroid hormone is a critical determinant for the regulation of the cochlear motor protein prestin. Proc Natl Acad Sci US A. 2002 Mar 5;99(5):2901-6. doi:10.1073 / pnas.052609899. Epub 2002 Feb 26. Erratum: Proc Natl Acad Sci US A 2002 May 28;99(11):7809. PMID:11867734; PMCID:PMC122445.
[0164] 31Ruel, J. et al. Impairment of SLC17A8 encoding vesicular glutamate transporter-3, VGLUT3, underlies nonsyndromic deafness DFNA25 and inner hair cell dysfunction in null mice. Am J Hum Genet 83, 278-292, doi: 10.1016 / j.ajhg.2008.07.008 (2008).
[0165] 32 Dressler, GR & Douglass, ECPax-2 Is a DNA-Binding Protein Expressed in Embryonic Kidney and Wilms-Tumor. P Natl Acad Sci USA 89, 1179-1183, doi: DOI 10.1073 / pnas.89.4.1179 (1992).
[0166] 33Tavassoli, K., Ruger, W. & Horst, J. Alternative splicing in PAX2 generates a new reading frame and an extended conserved coding region at the carboxy terminus. Hum Genet 101, 371-375, doi: DOI 10.1007 / s004390050644 (1997).
[0167] 34Ward, TA, Nebel, A., Reeve, AE & Eccles, MR Alternative Messenger-Rna Forms and Open Reading Frames within an Additional Conserved Region of the Human Pax-2 Gene. Cell Growth Differ 5, 1015-1021 (1994).
[0168] 35 Gibson, DG et al. Enzymatic assembly of DNA molecules up to several hundred kilobases. Nat Methods 6, 343-345, doi: 10.1038 / nmeth.1318 (2009).
[0169] 36 Hockemeyer, D. et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 29, 731-734, doi: 10.1038 / nbt.1927 (2011).
[0170] 37Slaymaker, IM et al. Rationally engineered Cas9 nucleases with improved specificity. Science 351, 84-88, doi: 10.1126 / science.aad5227 (2016).
[0171] 38Maruyama, T. et al. Increasing the efficiency of precise genome editing with CRISPR-Cas9 by inhibition of nonhomologous end joining. Nat Biotechnol 33, 538-U260, doi: 10.1038 / nbt.3190 (2015).
[0172] 39Hama, H. et al. ScaleS: an optical clearing palette for biological imaging. Nat Neurosci 18, 1518-1529, doi: 10.1038 / nn.4107 (2015).
[0173] 40Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573-3587e3529, doi: 10.1016 / j.cell.2021.04.048 (2021).
[0174] 41Rousseeuw, PJ. Silhouettes-a Graphical Aid to the Interpretation and Validation of Cluster-Analysis. J Comput Appl Math 20, 53-65, doi: Doi10.1016 / 0377-0427(87)90125-7(1987).
[0175] 42Love, MI, Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550, doi: 10.1186 / s13059-014-0550-8 (2014).
[0176] 43Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci USA 102, 15545-15550, doi: 10.1073 / pnas.0506580102 (2005).
[0177] 44Kolmykov, S. et al. GTRD: an integrated view of transcription regulation. Nucleic Acids Res 49, D104-D111, doi: 10.1093 / nar / gkaa1057 (2021).
[0178] 45 Locher, H. et al. Neurosensory development and cell fate determination in the human cochlea. Neural Dev 8, 20, doi: 10.1186 / 1749-8104-8-20 (2013).
Claims
1. A method for generating human cochlear hair cells, comprising: (a) Cultivation of PAX2b cells derived from human pluripotent stem cells in a medium containing a sonic hedgehog activator + Otic progenitor cells, which last about 5 days; and (b) subsequently, after step (a), culturing the cells of step (a) in a medium comprising a sonic hedgehog activator and a Wnt inhibitor for about 4 days (c) further culturing the cells of step (b) for a period of time sufficient to differentiate the cells into human cochlear hair cells expressing one or more of the following auris markers: PRESTIN, NR2F1, GATA3, INSM1, HES6, TMPRSS3 or GNG8.
2. The method according to claim 1, wherein the sonic hedgehog activator in steps (a) and (b) is purmorphamine.
3. The method of claim 2, wherein the concentration of purmorphamine is about 1 nM to about 1 mM.
4. The method of claim 1, wherein the Wnt inhibitor is IWP-2.
5. The method of claim 4, wherein the concentration of IWP-2 is about 1 nM to about 1 mM.
6. The method of claim 1, wherein culturing the otic progenitor cells with thyroxine begins about 39 days after the start of step (a) and continues for about 50 days.
7. The method of claim 6, wherein the concentration of thyroxine in the culture medium is about 250 ng / ml.
8. The method of claim 1, wherein the sufficient time is about 89 days after the start of step (a), and wherein about 11 days after the start of step (a), the culture medium does not contain additional agonists and inhibitors.
9. The method of claim 1, wherein the sufficient time is about 139 days after the start of step (a), and wherein about 11 days after the start of step (a), the culture medium does not contain additional agonists and inhibitors.
10. The method of claim 1, wherein about 98 days after initiation of step (a), the cochlear hair cells express two or more markers selected from the group consisting of PRESTIN, NR2F1, GATA3, and INSM1.
11. The method of claim 10, wherein about 98 days after initiation of step (a), the cells express PRESTIN, NR2F1, GATA3, and INSM1.
12. The method of claim 10 or 11, wherein about 98 days after initiation of step (a), the cells further express one or more additional markers selected from HES6, TMPRSS3 and GNG8.
13. The method of claim 1, wherein the method produces cells expressing two or more markers selected from the group consisting of PRESTIN, GATA3, INSM1, HES6, TMPRSS3, and GNG8 about 98 days after initiation of step (a).
14. The method of claim 1, wherein the method produces cells expressing three or more markers selected from the group consisting of PRESTIN, GATA3, INSM1, HES6, TMPRSS3, and GNG8 about 98 days after initiation of step (a).
15. The method of claim 1, wherein the otic progenitor cells are derived from pluripotent stem cells by: (a) culturing pluripotent stem cells on a coated plate in a culture medium comprising FGF-2, BMP-4 and a TGF-β inhibitor for about 3 days; (b) further culturing the cells of step (a) in a culture medium comprising FGF-2, a TGF-β inhibitor and a BMP-4 inhibitor for about 4 days; (c) further culturing the cells of step (b) in a culture medium comprising a GSK-3 inhibitor, a BMP-4 inhibitor and FGF-2 for about 4 days; and (d) further culturing the cells of step (c) on the coated plate in a medium containing a GSK-3 inhibitor for about 2 days to produce PAX2b + Ear progenitor cells. The method according to claim 17 , wherein the pluripotent stem cells are induced pluripotent stem cells or embryonic stem cells.
17. The method of claim 15, wherein the concentration of BMP-4 is greater than about 100 pg / ml.
18. The method of claim 15, wherein the concentration of BMP-4 is greater than about 500 pg / ml.
19. The method of claim 18, wherein the concentration of BMP-4 is about 100 pg / ml to about 1000 pg / ml.
20. The method of claim 18, wherein the concentration of BMP-4 is about 500 pg / ml to about 1000 pg / ml.
21. A method comprising: (a) culturing pluripotent stem cells on a coated plate in a medium comprising FGF-2, BMP-4 and SB431542 for about 3 days; (b) further culturing the cells of step (a) in a medium comprising FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium comprising CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) further culturing the cells of step (c) on the coated plate in a medium containing CHIR99021 for about 2 days to produce PAX2b + Progenitor cells.
22. The method of claim 21, further comprising: (e) culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in the culture medium for at least about 78 days to generate human cochlear hair cells.
23. The method of claim 22, wherein the culture medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
24. A method comprising: (a) culturing pluripotent stem cells on a coated plate in a medium comprising FGF-2, BMP-4 and SB431542 for about 3 days; (b) further culturing the cells of step (a) in a medium comprising FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium comprising CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) further culturing the cells of step (c) on the coated plate in a medium comprising CHIR99021 for about 2 days; (e) further culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in the culture medium for at least about 78 days to generate human cochlear hair cells.
25. The method of claim 24, wherein the culture medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
26. A method comprising: (a) culturing pluripotent stem cells on a coated plate in a medium comprising FGF-2, BMP-4 and SB431542 for about 3 days; (b) further culturing the cells of step (a) in a medium comprising FGF-2, SB431542 and LDN193189 for about 4 days; (c) further culturing the cells of step (b) in a medium comprising CHIR99021, LDN193189 and FGF-2 for about 4 days; (d) further culturing the cells of step (c) on the coated plate in a medium comprising CHIR99021 for about 2 days; (e) further culturing the cells of step (d) in a medium comprising CHIR99021 and purmorphamine for about 5 days; (f) further culturing the cells of step (e) in a medium comprising CHIR99021, purmorphamine and IWP-2 for about 4 days; (g) further culturing the cells of step (f) in a culture medium for about 28 days; (h) further culturing the cells of step (g) in a medium containing thyroxine for about 50 days to generate human cochlear hair cells.
27. The method of claim 26, wherein the culture medium in step (g) does not contain CHIR99021, purmorphamine and IWP-2.
28. A human cochlear hair cell produced by the method of any one of claims 1-19 or 22-27.
29. An organoid comprising the cochlear hair cell of claim 28.
30. A kit, platform or system comprising: (a) an activator of Sonic Hedgehog; and (b) Wnt inhibitors.
31. The kit, system or platform of claim 30, wherein the kit, system or platform further comprises: (c) FGF-2; (d) TGF-β inhibitors; (e) BMP-4 inhibitors; and (f) GSK-3 inhibitors.
32. The kit, system or platform of claim 30 or 31, further comprising: (g) Thyroxine.
33. The kit, system or platform of any one of claims 30-32, wherein the kit, system or platform further comprises: (h) Induced pluripotent stem cells or embryonic stem cells.
